

Form 78.05

District of: Nova Scotia
Division of: 01-Halifax
Court No. 45907
Estate No. 51-3134197

Bankruptcy Court

DEC 20 2024

Halifax, N.S.

**Supreme Court of Nova Scotia
In Bankruptcy and Insolvency**



In the matter of the Notice of Intention to make a proposal of Motryx Inc. pursuant to the Bankruptcy and Insolvency Act, R.S.C. 1985, c. B-3, as amended

Sale and Investment Solicitation Process Order

Before the Registrar in Bankruptcy Raffi A. Balmanoukian in chambers

THIS MOTION made by Motryx Inc. (the "**Applicant**" or the "**Company**") pursuant to the *Bankruptcy and Insolvency Act*, R.S.C. 1985, c B-3, as amended, (the "**BIA**") for an order abridging the time to hear this motion, if required, and approving the Sale and Investment Solicitation Process;

ON READING the Third Report of BDO Canada Limited, in its capacity as Proposal Trustee of the Applicant (the "**Proposal Trustee**")


ON HEARING the submission of counsel for the Applicant and the Proposal Trustee, and such other counsel that were present, and no one else appearing for any party although duly served;

SERVICE

1. **THIS COURT ORDERS** that the time for service of the Notice of Motion and the materials filed as set out in the affidavit of service is hereby deemed adequate notice so that this Motion is properly returnable on December 20, 2024, and hereby dispenses with further service thereof;
2. **THIS COURT ORDERS** that the proposed Sale and Investment Solicitation Process attached hereto as Schedule "A" (the "**SISP**") be and is hereby approved;
3. The Proposal Trustee is hereby authorized and directed to take such steps as it deems necessary or advisable to carry out and perform its obligations under the SISP;
4. The Stalking Horse Asset Purchase Agreement (the "**Agreement**") between the Company and Aerocom GMBH & Co. dated December 13, 2024, and attached as Appendix "A" to the SISP is approved and accepted for the purpose of the SISP. For greater certainty, approval of the Agreement at this time does not include approval for any sale arising from the SISP; and

5. **THIS COURT ORDERS** that this order and all its provisions are effective as of 12:01 a.m. December 20, 2024,

Issued December 20, 2024


Deputy Registrar

SHYLA FURLONG
Deputy Registrar of
Bankruptcy

Sale and Investment Solicitation Process**Background**

1. On September 27, 2024, (the "**Company**") filed a Notice of Intention to Make a Proposal pursuant to the terms of *Bankruptcy and Insolvency Act* ("**BIA**").
2. BDO Canada Limited, was appointed as proposal trustee during the BIA proceedings (the "**Proposal Trustee**").
3. The Company will apply to the Court seeking an Order approving the sale and investment solicitation process (the "**Sale Process**") described herein (the "**Sale Process Approval Order**"). The Sale Process Approval Order will also approve the Stalking Horse Asset Purchase Agreement (the "**Stalking Horse Agreement**") between the Company and Aerocom GMBH & Co. (the "**Stalking Horse Purchaser**") which appears as Appendix "A" to the Sales Process for the limited purpose of approving the Stalking Horse Purchaser as an approved bidder under the Sales Process.
4. The Proposal Trustee will conduct the Sale Process described herein. Under the Sale Process, all qualified interested parties will be provided with an opportunity to participate in the Sale Process. The Sale Process is intended to continue the pre-filing efforts of the Company in soliciting interest in the property, business, assets, shares, investments and/or undertakings (collectively, the "**Assets**") of the Company (the "**Transaction**").
5. The purpose of this Sale Process is to determine whether a more favourable Transaction than the Stalking Horse Agreement may be obtained through a formal marketing process conducted by the Proposal Trustee and approved by the Court. For the purposes of this Sale Process, a "**Superior Offer**" shall mean:
 - (a) a credible, reasonably certain and financially viable offer made by a Qualified Bidder (as defined herein) to be a counterparty to a Transaction, the terms of which offer are more favorable and no more burdensome or conditional than the terms contained in the Stalking Horse Agreement; and
 - (b) an offer that provides for cash consideration of the Purchase Price of \$400,000.00 (as defined herein) plus \$35,000.00 to fund reimbursement of the expenses incurred by the Stalking Horse Bidder.
6. The Sale Process Approval Order, and any other orders of the Court made in this proceeding relating to the Sale Process, shall exclusively govern the process for soliciting and selecting bids for the sale of the Assets or investment in the Company, free and clear of any and all liabilities and encumbrances.
7. Unless otherwise indicated herein, any event that occurs on a day that is not a Business Day shall be deemed to occur on the next Business Day (a "**Business Day**" is any day, other than a Saturday or Sunday, on which banks are ordinarily open for business in Halifax, Nova Scotia).

Timeline

8. The following table sets out the key milestones under the Sale Process:

Milestones	Deadline
Publish notice of Sales Process and deliver Teaser Letter and NDA to known potential bidders	December 30 ²³ , 2024
Bid Deadline	February 7, 2025
Deadline to top-up Deposit	February 12, 2025
Auction	February 14, 2025
Closing Date	No Later than February 28, 2025, subject to the availability of the Court

9. Subject to the terms contained herein and any order of the Court, the dates set out in the Sale Process may be extended by the Proposal Trustee, in its sole discretion, acting reasonably, all with a view to completing a fair and reasonable sale or investment in the Company.

Publication Notice

10. Within seven (7) calendar days of the Sale Process being approved by the Court, the Proposal Trustee shall publish notice of this Sale Process in any publications considered appropriate by the Proposal Trustee.

Solicitation of Interest

11. As soon as reasonably practicable, the Proposal Trustee will prepare an initial offering summary (the "Teaser Letter") notifying prospective purchasers of the existence of the Sale Process and inviting prospective purchasers to express their interest in making an offer in respect of the Assets pursuant to the terms of the Sale Process.

Free of Any and all Claims and Interests

12. All of the Assets of the Company can be transferred free and clear of all liens and claims, subject to any permitted encumbrances, pursuant to an approval and vesting Order issued by the Court approving the Transaction (the "Approval and Vesting Order"). For greater certainty, liens and claims will be discharged and any security interest will only attach to the net proceeds

of such Transaction following the granting of the Approval and Vesting Order.

"As Is, Where Is"

13. Any purchase of the Assets or an investment in the Company will be on an "as is, where is" basis without representations or warranties of any kind, nature or description by the Company, or any of their respective directors, officers, partners, employees, agents, advisors or estates, except to the extent as may be set forth in a Binding APA (as defined herein) and approved by the Court. By submitting a bid, each Potential Bidder (as defined herein) shall be deemed to acknowledge and represent that it has had an opportunity to conduct any and all due diligence regarding the Company and its Assets prior to making its bid, that it has relied solely upon its own independent review, investigation and/or inspection of any documents and the Company's Assets in making its bid, and that it did not rely upon any written or oral statements, representations, warranties or guarantees, express, implied, statutory or otherwise, regarding the Company or its Assets or the completeness of any information provided in connection therewith, except as expressly stated in this Sale Process or as set forth in a Binding APA and approved by the Court.

Participation Requirements

14. Each person who wishes to participate in the Sale Process (a "**Potential Bidder**") must deliver an executed non-disclosure agreement ("**NDA**"), in the form attached herein as Schedule "B", to the Proposal Trustee prior to the distribution of any confidential information as follows:
Attn: Neil Jones, nejones@bdo.ca.

15. If it is determined by the Proposal Trustee, in its sole discretion, that a Potential Bidder: (i) has a *bona fide* interest in pursuing a Transaction; and (ii) has delivered an executed NDA, then such Potential Bidder will be deemed to be a "**Qualified Bidder**".

16. The Proposal Trustee will prepare, with the assistance of the Company, and send to each Qualified Bidder, as soon as reasonably practicable, a confidential information memorandum, which will provide, among other things, information considered relevant to the Sale Process.

Due Diligence

17. The Proposal Trustee, with the assistance of the Company, subject to competitive and other business considerations, may give each Qualified Bidder such access to due diligence materials and information relating to the Company as the Proposal Trustee deems appropriate, in its sole discretion. Due diligence access may include access to an electronic data room (a "**Data Room**"), on-site inspections and other matters which a Qualified Bidder may reasonably request and as to which the Company may agree. Neither the Company, the Proposal Trustee nor any of their representatives will be obligated to furnish any information relating to the Company to any person, in their discretion. The Company and the Proposal Trustee make no representation or warranty, express or implied, as to the information provided through this due diligence process or otherwise, except as may be set forth in a Binding APA with the Successful Bidder (as defined herein).

Bid Deadline

18. A Qualified Bidder that desires to make a bid shall deliver written copies of its bid, in the form of the template APA located in the Data Room, together with a blackline outlining all changes made to the APA (a "**Binding APA**"), to the Proposal Trustee as follows: Attn: Neil Jones at nejones@bdo.com, so as to be received by no later than **February 7, 2025 at 5:00 p.m.** (Atlantic Standard Time) (as may be extended as set out below, the "**Bid Deadline**"). The Proposal Trustee may extend the Bid Deadline, once or successively, but is not obligated to do so. If the Bid Deadline is extended, the Proposal Trustee will promptly notify all Qualified Bidders.

Binding APA

19. A Binding APA must comply with all of the following:

- (a) the bid is an offer to purchase all, or substantially all, of the Assets on terms and conditions acceptable to the Proposal Trustee and delivered to the Proposal Trustee prior to the Bid Deadline;
- (b) it is duly authorized and executed, and includes a purchase price for the Assets expressed in Canadian dollars (the "**Purchase Price**"), together with all exhibits, schedules and all applicable ancillary agreements thereto;
- (c) includes a letter of acknowledgment stating that the Qualified Bidder's offer is irrevocable and open for acceptance until the Successful APA is selected by the Company;
- (d) it is accompanied by written evidence of a firm, irrevocable commitment for financing or other evidence satisfactory to the Proposal Trustee, in its sole discretion, of the ability of the Qualified Bidder to consummate the proposed Transaction, and that will allow the Proposal Trustee to make a determination as to the Qualified Bidder's financial and other capabilities to consummate the proposed sale and pay the Purchase Price;
- (e) it fully discloses the identity of each entity that will be bidding for the Assets or otherwise sponsoring, financing, participating or benefiting from such bid;
- (f) it includes an acknowledgement and representation of the Qualified Bidder that:
 - (i) it has had an opportunity to conduct any and all due diligence regarding the Assets and the Company prior to making its bid, (ii) it has relied solely upon its own independent review, investigation and/or inspection of any documents in making its bid, and (iii) it did not rely upon any written or oral statements, representations, warranties, or guarantees whatsoever, whether express, implied, statutory or otherwise, regarding the Assets, the Company or the completeness of any information provided in connection therewith;
- (g) it includes evidence, in form and substance reasonably satisfactory to the Company, of authorization and approval from the Qualified Bidder's board of directors (or comparable governing body) with respect to the submission, execution and delivery of the Binding APA submitted by the Qualified Bidder;

- (h) provides a deposit in the amount of not less than 10% of the Purchase Price offered by the Qualified Bidder (the "**Deposit**");
- (i) it is received by the Proposal Trustee by the Bid Deadline; and,
- (j) the bid contemplates closing the transaction set out therein within 10 Business Days of the Approval and Vesting Order (the "**Closing Date**").

20. The Proposal Trustee may, in its sole discretion, determine whether to entertain bids for the Assets that do not conform to one or more of the requirements specified herein.

21. For greater certainty, the Stalking Horse Agreement shall be deemed to be a Binding APA.

Evaluation of Binding APA

22. Each submitted Binding APA will be considered by the Proposal Trustee based upon several factors including, without limitation, items such as the Purchase Price and the net value provided by such bid, the claims likely to be created by such bid in relation to other bids, the counterparties to such transactions, the proposed transaction documents, other factors affecting the speed and certainty of the closing of the transaction, the value of the transaction, the Assets included or excluded from the bid, the transition services required from the Company (if any), any related transaction costs, the likelihood and timing of consummating such transactions, whether the Transaction results in a Superior Offer, and such other matters as the Proposal Trustee determines in its sole discretion.

23. Each Qualified Bidder shall comply with all reasonable requests for additional information by the Proposal Trustee regarding the Qualified Bidder or the Binding APA. Failure of a Qualified Bidder to comply with such requests for additional information will be a basis for the Proposal Trustee to reject a Binding APA.

Auction

24. If the Proposal Trustee receives at least one additional Qualified Bid in addition to the Stalking Horse Bid, the Proposal Trustee will conduct and administer an Auction in accordance with the terms of this Sales Process (the "**Auction**"). Instructions to participate in the Auction, which will take place via video conferencing, will be provided to Qualified Parties (as defined below) not less than 24 hours prior to the Auction.

25. Only parties that provided a Qualified Bid by the Bid Deadline, as confirmed by the Proposal Trustee, including the Stalking Horse Bid (collectively, the "**Qualified Parties**"), shall be eligible to participate in the Auction. No later than 5:00 p.m. (Atlantic Standard Time) on the day prior to the Auction, each Qualified Party must inform the Proposal Trustee whether it intends to participate in the Auction. The Proposal Trustee will promptly thereafter inform in writing each Qualified Party who has expressed its intent to participate in the Auction of the identity of all other Qualified Parties that have indicated their intent to participate in the Auction. If no Qualified Party provides such expression of intent, the Stalking Horse Bidder shall be the Successful Bid (as defined below).

Auction Procedure

26. The Auction shall be governed by the following procedures:

a. **Participation at the Auction.** Only the Qualified Parties, including the Stalking Horse Bidder, the Proposal Trustee and each of their respective advisors will be entitled to attend the Auction, and only the Qualified Parties will be entitled to make any subsequent Overbids (as defined below) at the Auction. The Proposal Trustee shall provide all Qualified Bidders with the details of the lead bid by 5:00 PM (Atlantic Standard Time) two (2) Business Days after the Bid Deadline. Each Qualified Bidder must inform the Proposal Trustee whether it intends to participate in the Auction no later than 5:00 PM (Atlantic Standard Time) on the Business Day prior to the Auction;

b. **No Collusion.** Each Qualified Party participating at the Auction shall be required to confirm on the record at the Auction that: (i) it has not engaged in any collusion with respect to the Auction and the bid process; and (ii) its bid is a good-faith bona fide offer, and it intends to consummate the proposed transaction if selected as the Successful Bid;

c. **Minimum Overbid.** The Auction shall begin with the Qualified Bid that represents the highest or otherwise best Qualified Bid as determined by the Proposal Trustee (the "Initial Bid"), and any bid made at the Auction by a Qualified Party subsequent to the Proposal Trustee's announcement of the Initial Bid (each, an "Overbid"), must proceed in minimum additional cash increments of \$25,000;

d. **Bidding Disclosure.** The Auction shall be conducted such that all bids will be made and received in one group video-conference, on an open basis, and all Qualified Parties will be entitled to be present for all bidding with the understanding that the true identity of each Qualified Party will be fully disclosed to all other Qualified Parties and that all material terms of each subsequent bid will be fully disclosed to all other Qualified Parties throughout the entire Auction by video conference room, or such other method of communication the Proposal Trustee advises; provided, however, that the Proposal Trustee, in its discretion, may establish separate video conference rooms to permit interim discussions between the Proposal Trustee and individual Qualified Parties with the understanding that all formal bids will be delivered in one group video conference, on an open basis;

e. **Bidding Conclusion.** The Auction shall continue in one or more rounds and will conclude after each participating Qualified Party has had the opportunity to submit one or more additional bids with full knowledge and written confirmation of the then-existing highest bid(s);

f. **No Post-Auction Bids.** No bids will be considered for any purpose after the Auction has concluded; and

g. **Auction Procedures.** The Proposal Trustee shall be at liberty to set additional procedural rules at the Auction as it sees fit.

Selection of Successful APA

27. Before the conclusion of the Auction, the Proposal Trustee will review and evaluate each Binding APA and: (i) the Proposal Trustee may identify the highest or otherwise best offer for the Assets (the "**Successful Bid**"), or (ii) if no Binding APAs, other than the Stalking Horse Agreement, have been received by the Bid Deadline, then the Proposal Trustee shall declare the Stalking Horse Agreement as the Successful Bid.

28. Notwithstanding the foregoing, a Binding APA may not be withdrawn, modified or amended without the written consent of the Proposal Trustee prior to the Successful Bid being determined. Any such withdrawal, modification or amendment made without the written consent of the Proposal Trustee prior to the Successful Bid being determined shall result in the forfeiture of such Qualified Bidder's Deposit as liquidated damages and not as a penalty.

29. In the event a Binding APA is not selected as a Successful Bid, the Deposit (without interest) shall be returned to the Qualified Bidder as soon as reasonably practicable.

Sale Approval Motion Hearing

30. The motion for an Order of the Court approving any Successful Bid (the "**Sale Approval Motion**") shall be brought by the Proposal Trustee and shall be heard on a date determined by Proposal Trustee and subject to the Court's availability.

31. All of the Binding APAs other than the Successful Bid, if any, shall be deemed rejected by the Proposal Trustee on and as of the date of closing of the Transaction contemplated by the Successful Bid.

Deposits

32. All Deposits received pursuant to this Sales Process shall be held in trust by the Proposal Trustee (Attn: Neil Jones, nejones@bdo.com) in a noninterest bearing account. The Proposal Trustee shall hold Deposits paid by each of the Bidders in accordance with the terms outlined in this Sales Process. In the event that a Deposit is paid pursuant to this Sales Process, and the Proposal Trustee elects not to proceed to negotiate and settle the terms and conditions of a definitive agreement with the Person that paid such Deposit, the Proposal Trustee shall return the Deposit to that Person. In the event that the Successful Bidder defaults in the payment or performance of any obligations owed to the Proposal Trustee pursuant to any Final Agreement, the Deposit paid by the Successful Bidder, as applicable, shall be forfeited as liquidated damages and not as a penalty.

Reservation of Rights

33. The Proposal Trustee, may: (a) determine which Binding APA, if any, is the highest or otherwise best offer; (b) notwithstanding anything contained herein, reject any bid that is (i) inadequate or insufficient as determined by the Proposal Trustee, in its sole discretion, (ii) not in conformity with the requirements of the Sale Process or any order of the Court, or (iii) contrary to the best interests of the Company as determined by the Proposal Trustee in its sole discretion, and (c) may modify the Sale Process or impose additional terms and conditions on the sale of the Assets at any time in its sole discretion.

Miscellaneous

34. This Sale Process is solely for the benefit of the Company and nothing this Sale Process shall create any rights in any other person or bidder (including without limitation rights as third party beneficiaries or otherwise).

35. The Court shall retain jurisdiction to hear and determine all matters arising from or relating to the implementation of this Sale Process.

Schedule "A"

Stalking Horse Agreement

AEROCOM GMBH & Co. and/or its permitted assignee

the Purchaser

and

MOTRYX INC.

the Vendor

STALKING HORSE ASSET PURCHASE AGREEMENT

December 13, 2024

TABLE OF CONTENTS

ARTICLE 1 INTERPRETATION	5
Section 1.1 Defined Terms.....	5
Section 1.2 References and Usage.....	10
Section 1.3 Headings, etc.....	10
Section 1.4 Schedules.....	10
ARTICLE 2 PURCHASE AND SALE.....	11
Section 2.1 Purchased Assets.....	11
Section 2.2 Excluded Assets.....	13
Section 2.3 Assignment and Assumption of Consent Required Contracts.....	13
ARTICLE 3 PURCHASE PRICE.....	14
Section 3.1 Purchase Price.....	14
Section 3.2 Payment of the Purchase Price.....	14
Section 3.3 Purchase Price Allocation.....	14
Section 3.4 No Effect on Other Rights.....	14
ARTICLE 4 TAX MATTERS.....	14
Section 4.1 Transfer Taxes.....	14
Section 4.2 Tax Elections.....	14

Ch.

ARTICLE 5 REPRESENTATIONS AND WARRANTIES	15
Section 5.1 Representations and Warranties of the Vendor.....	15
Section 5.2 Representations and Warranties of the Purchaser.....	16
Section 5.3 No Other Representations or Warranties.....	16
Section 5.4 As Is, Where Is.....	17
ARTICLE 6.....	17
Section 6.1 Access by Purchaser.....	17
Section 6.2 Access by Proposal Trustee.....	18
Section 6.3 Title and Risk.....	18
Section 6.4 Employees.....	18
Section 6.5 Notices and Requests for Consents.....	19
Section 6.6 Transfer of the Purchased Assets.....	19
Section 6.7 Actions to Satisfy Closing Conditions.....	19
ARTICLE 7 SALES PROCESS	19
Section 7.1 Compliance with Sale Process.....	19
Section 7.2 Expense Reimbursement.....	19
ARTICLE 8 CONDITIONS OF CLOSING	21
Section 8.1 Conditions for the Benefit of the Purchaser.....	21
Section 8.2 Conditions for the Benefit of the Vendor.....	22
Section 8.3 Conditions for the Benefit of the Purchaser and the Vendor.....	23
ARTICLE 9 CLOSING.....	23
Section 9.1 Date, Time and Place of Closing.....	23
Section 9.2 Closing Procedures.....	23
Section 9.3 Proposal Trustee's Certificate.....	23
ARTICLE 10 TERMINATION.....	24
Section 10.1 Termination Rights.....	24
Section 10.2 Effect of Termination.....	24
ARTICLE 11 MISCELLANEOUS.....	25
Section 11.1 Notices.....	25
Section 11.2 Time of the Essence.....	26
Section 11.3 Third Party Beneficiaries.....	26
Section 11.4 Expenses.....	26
Section 11.5 Amendments.....	26
Section 11.6 Waiver.....	27
Section 11.7 Entire Agreement.....	27
Section 11.8 Successors and Assigns.....	27
Section 11.9 Severability.....	27
Section 11.10 Governing Law and Jurisdiction.....	27
Section 11.11 Counterparts.....	27
SCHEDULES.....	29
Schedule 1.1(a) – Assumed Contracts.....	30
Schedule 1.1(b) – Consent Required Contracts	33
Schedule 1.1(c) – Excluded Assets.....	34
Schedule 1.1(d) – Excluded Contracts.....	35

Schedule 1.1(e) – Assumed Liabilities.....	36
Schedule 1.1(f) – Intellectual Property	37
Schedule 1.1(g) – Licenses	44
Schedule 1.1(h) – Sale Process	45
Schedule 2.1(a,1) – Personal and moveable property	46
Schedule 2.1(a,2) – Accessories.....	50
Schedule 2.1(h) – Claims	53

STALKING HORSE ASSET PURCHASE AGREEMENT

This stalking horse asset purchase agreement is dated December 13, 2024, between Motryx, as vendor (the "Vendor") and Aerocom GMBH & Co. and/or its permitted assignee, as purchaser (the "Purchaser", together with the Vendor, the "Parties" and each a "Party").

RECITALS:

- (1) The Vendor's business consists of the marketing and distribution of a unique technology it has developed to help ensure the safe transport of blood samples, urine samples or other biological samples in pneumatic transport systems (PTS) to hospitals and laboratories, to facilitate the assessment by the recipients of such samples for potential damage during transportation and to help adjust the transport systems to reduce the rejection of samples in the future. This unique technology is known as "VitalQC" and consists of two components, being the VitalVial and the VitalApp. The VitalVial is a container with a similar configuration to the samples subject to transportation (generally it is vial-shaped). This contains a hardened substrate component in which at least one reusable sensing device that detects the transport parameters of the samples is embedded. The transport parameters determine the ability to use the sample. The VitalVial can be coupled, either directly or via a network such as the Internet, to a peripheral device such as a laptop, smart phone, tablet, flash drive, database or a server, onto which the data collected is transmitted, computerized and saved. The Vendor has applied for and obtained patents for the VitalVial and the method to make it. The Vendor has also developed the VitalApp, a cloud based application which allows for the automatic analysis and interpretation of the data collected by the VitalVials by using web-based data analytics. The VitalQC technology is supported by clinical research proving it to be a unique solution to an existing problem in the pre-analytical stage of diagnostic laboratory testing. The Vendor's products enable hospitals and laboratories that are planning to use blood and other biological samples to determine whether they are suitable for patient care. The Vendor markets and distributes its technology to hospitals and laboratories (the "Business").
- (2) On September 27, 2024, the Vendor filed a Notice of Intention to Make a Proposal under the *Bankruptcy and Insolvency Act* (the "Proposal Proceedings") and BDO Canada Limited was appointed as proposal trustee (the "Proposal Trustee").
- (3) The Vendor intends to bring an application for an Order by the Supreme Court of Nova Scotia (the "Court"), among other things approving a Court-supervised "stalking horse" Sale Process (as defined below).
- (4) In connection with the proposed Sale Process to be carried out by the Proposal Trustee, the Purchaser, as a "stalking horse bidder", has agreed to purchase, and the Vendor has agreed to sell, the Purchased Assets pursuant to and in accordance with the terms of the Sale Process and subject to and in accordance with the conditions of this Agreement.
- (5) The transactions contemplated by this Agreement are subject to the approval of the Court and will be consummated only pursuant to the Approval and Vesting Order to be obtained in the Proposal Proceedings.

NOW THEREFORE in consideration of the mutual covenants and agreements contained in this Agreement and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged), the Parties agree as follows:

- 5 -
ARTICLE 1
INTERPRETATION

Section 1.1 Defined Terms.

As used in this Agreement (including the recitals above), the capitalized terms listed below shall have the corresponding meanings.

"Agreement" means this Asset Purchase Agreement and all attached Schedules, in each case as the same may be supplemented, amended, restated or replaced from time to time, and the expressions "hereof", "herein", "hereto", "hereunder", "hereby" and similar expressions refer to this Agreement and all attached Schedules and unless otherwise indicated, references to Articles, Sections and Schedules are to Articles, Sections and Schedules in this Agreement.

"Ancillary Agreements" means all agreements, certificates and other instruments delivered or given pursuant to this Agreement.

"Approval and Vesting Order" means an approval and vesting order of the Court in form and in substance satisfactory to the Vendor and the Purchaser, each acting reasonably, approving this Agreement and vesting in and to the Purchaser the Purchased Assets, free and clear of and from any and all Encumbrances to the extent and as provided for in such approval and vesting order.

"Assignment Order" means an order or orders of the Court, in form and substance satisfactory to the Purchaser, acting reasonably, authorizing and approving the assignment of one or more Consent Required Contracts for which the consent, approval or waiver of the party or parties thereto (other than the Vendor) required to assign such Consent Required Contracts has not been obtained by Closing.

"Assumed Contracts" means the supply contracts, the subscription agreements, the customer contracts, the lease for storage space, the licenses, the purchase orders, the order forms and the confidentiality agreements relating to the Business, all of which are listed in Schedule 1.1 (a) and shall not include the Excluded Contracts.

"BIA" means the *Bankruptcy and Insolvency Act*, R.S.C. 1985, c. B-3.

"Books and Records" means all information in any form relating to the Purchased Assets and the Business, including books of account, financial information, operations, sales books, tax, business, marketing, personnel and research information and records, technical information, customer onboarding materials, drill logs, equipment logs, technical reports, training manuals and materials, customer support levels and response times, operating guides and manuals, assembly and shipment procedures, information on the hardware, firmware, design and safety measures and all other documents, files, correspondence and other information, including all data, information and databases stored on computer-related or other electronic media, but excluding the minute books and corporate records of the Vendor.

"Business" has the meaning specified in the preamble to this Agreement.

"Business Day" means any day of the year, other than a Saturday, Sunday or any day on which major Canadian chartered banks are closed for business in the Province of Nova Scotia or the federal laws of Canada applicable in the Province of Nova Scotia.

"Canada's Anti-Spam Law" or "CASL" has the meaning specified in Section 1.1(k).

"Claims" has the meaning specified in Section 2.1(h).

"Closing" means the completion of the transaction of purchase and sale contemplated in this Agreement.

"Closing Date" means the date on which the Closing occurs, which date shall be no later than five (5) business days from the issuance of the Approval and Vesting Order or such other date as mutually agreed between the Parties and the Proposal Trustee.

"Consent Required Contract" means any Assumed Contract or License that is material to the Business, which is not assignable in whole or in part without the consent, approval or waiver of the party or parties thereto (other than the Vendor). All of the Consent Required Contracts are listed in Schedule 1.1 (b).

"Contract" means all contracts, letters of intent, licenses, leases, agreements, obligations, promises, undertakings, arrangements, documents, commitments, entitlements or engagements, NDA and confidentiality agreements, invoices, order forms, purchase orders, memberships, trial memberships, and the "validation only", the "advanced reporting", and other periodic subscription agreements including but not limited to courier/research, contracts with channel partners, EQA providers, courier companies, and research companies to which the Vendor is a party or by which the Vendor is bound relating to the Purchased Assets and/or the Business, all as may be amended and/or restated, and including any and all related quotations, orders, proposals or tenders which remain open for acceptance, warranties and guarantees and documents ancillary thereto.

"Cure Costs" means, in respect of any Consent Required Contract for which an Assignment Order is required, all amounts owing as at the Closing Date by the Vendor pursuant to such Consent Required Contract and all amounts required to be paid to cure any monetary defaults thereunder, if any, required to effect an assignment thereof from the Vendor to the Purchaser, together with any fee or other monetary concession approved by the Purchaser and granted in connection with obtaining any Assignment Order for such Consent Required Contract, including all administrative fees and counsel fees of the counterparties required to be paid to obtain such Assignment Order.

"DIP Lender" means AEROCOM GMBH & Co.

"DIP Loan" means the debtor in possession loan made by Aerocom GMBH & Co., to the Vendor in the amount of \$360,000.00, plus any accrued interest and fees pursuant to the DIP Loan Agreement and any amendments thereto, together with any additional debtor in possession financing agreed to by the Vendor and the DIP Lender and approved by the Court.

"DIP Loan Agreement" means the DIP Term Sheet as approved by the Court in the Proposal Proceedings and as may be amended and restated or modified from time to time.

"Employee Plan" means all:

- (a) contracts, agreements, plans, arrangements or policies (written or oral) providing for incentive compensation, deferred compensation, bonuses, profit-sharing, severance or termination pay, share appreciation, share option, share

purchase or other stock related rights relating to the Business; and

- (b) health or other medical benefits (other than the Canadian Pension Plan, the Nova Scotia Health Insurance Program and other similar health plans established and administered by any other province and workers' compensation insurance provided pursuant to applicable Law), life or other insurance (including any self-insured arrangements), dental, disability, salary continuation, vacation, automobile, supplemental unemployment benefits, post-employment, retirement or supplemental retirement benefits (including compensation, health, medical or life insurance benefits);

which are maintained, administered or contributed to by or on behalf of the Vendor and which covers any employee or former employee of the Vendor.

"Employees" means any and all (i) employees who are actively at work (including full-time, part-time or temporary employees) of the Vendor; and (ii) employees of the Vendor who are on leaves of absence (including maternity leave, parental leave, disability leave, sickness leave and other statutory leaves) as at the Closing Date.

"Encumbrance" means any mortgage, charge, pledge, hypothec, security interest, deemed trust (statutory or otherwise), assignment, lien (statutory or otherwise), leases, rights of way, title defects, options, claim, adverse claims, encumbrances, easement, title retention agreement or arrangement, conditional sale, deemed or statutory trust, restrictive covenant or other encumbrance of any nature which, in substance, secures payment or performance of an obligation.

"Excluded Assets" has the meaning specified in Section 2.2. The Excluded Assets are listed in Schedule 1.1 (c).

"Excluded Contracts" means all of the Contracts listed in Schedule 1.1(d).

"Excluded Liabilities" means any and all liabilities and obligations of the Vendor of whatever kind including, without limitation, liabilities in respect to the Business and the Non- Transferred Employee Liabilities except for those liabilities listed in Schedule 1.1(e) - which the Purchaser has specifically agreed to assume.

"Expense Reimbursement" has the meaning specified in Section 7.2(a).

"Governmental Authorities" means governments, regulatory authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, Crown corporations, courts, bodies, boards, tribunals or dispute settlement panels or other law or regulation-making organizations or entities: (i) having or purporting to have jurisdiction on behalf of any nation, province, territory, state or other geographic or political subdivision thereof; or (ii) exercising, or entitled or purporting to exercise any administrative, executive, judicial, legislative, policy, regulatory or taxing authority or power.

"HST" means all goods and services tax and harmonized sales tax imposed under Part IX of the *Excise Tax Act* (Canada) or any other statute in any jurisdiction of Canada.

"Intellectual Property" means all intellectual property of the Vendor used by or currently being developed for use in the Business listed in Schedule 1.1 (f), and all rights, interests and benefits of the Vendor, through ownership, licensing or otherwise to such Intellectual Property, including without limitation:

- (a) all patents, patent applications and other patent rights, including provisional and continuation patents;
- (b) all registered and unregistered trademarks, service marks, logos, slogans, corporate names, business names and other indicia of origin, and all applications and registrations therefor;
- (c) registered and unregistered copyrights and mask works, including all copyright in and to computer software programs and applications and registrations of such copyright;
- (d) internet domain names, applications and reservations for internet domain names, uniform resource locators and the corresponding internet sites;
- (e) industrial designs;
- (f) trade secrets and proprietary information not otherwise listed in (a) through (e) above, including, without limitation, all inventions (whether or not patentable), invention disclosures, moral and economic rights of authors and inventors (however denominated), confidential information, technical data, in-house assembly manuals and work descriptions, customer lists, sales strategies, pricing schemes, corporate and business names, trade names, trade dress, brand names, know-how, mask works, circuit topography, formulae, methods (whether or not patentable), designs, processes, procedures, technology, business methods, source codes, object codes, computer software programs (in either source code or object code form), databases, data collections and other proprietary information or material of any type, and all derivatives, improvements and refinements thereof, howsoever recorded or unrecorded;
- (g) any applications or registrations of the foregoing, issued patents, continuations in part, divisional applications or analogous rights therefor, in each case whether registered or not; and
- (h) all Licenses in respect to any intellectual property.

"Laws" means any principle of common law and all applicable (i) laws, constitutions, treaties, statutes, codes, ordinances, orders, decrees, rules, regulations and by-laws; (ii) judgments, orders, writs, injunctions, decisions, awards and directives of any governmental entity; and (iii) to the extent that they have the force of law, standards, policies, guidelines, notices and protocols of any governmental entity.

"Licenses" means all licenses, sub-licenses, subscriptions and other agreements by or through which other Persons grant the Vendor exclusive or non-exclusive rights or interests in or to any Intellectual Property that is used in connection with the Business, all of which are listed in Schedule 1.1 (g).

"Non-Transferred Employee Liabilities" means all liabilities relating to the Non-Transferred Employees, including Wages, vacation pay, termination costs, notice or pay in lieu of notice, severance, wrongful and constructive dismissal damages, human rights claims, all liabilities pursuant to any Employee Plan.

"Non-Transferred Employees" means all Employees who are not Transferred Employees.

"Notice" has the meaning specified in Section 11.1.

"Offerees" has the meaning specified in Section 6.4(a).

"Parties" has the meaning specified in the recitals above.

"Person" means an individual, partnership, limited partnership, limited liability partnership, corporation, limited liability company, unlimited liability company, joint stock company, trust, unincorporated association, joint venture or other entity and pronouns have a similarly extended meaning.

"Proposal Trustee" has the meaning specified in the recitals above.

"Proposal Trustee's Certificate" has the meaning specified in Section 9.3.

"Purchase Price" has the meaning specified in Section 3.1.

"Purchased Assets" has the meaning specified in Section 2.1.

"Purchaser" has the meaning specified in the preamble above.

"Sale Process" means the sale solicitation process set forth in Schedule 1.1(h) – as approved by the Court on October 22, 2024, as may be amended or otherwise modified from time to time in accordance with the terms therein.

"Successful Bid" has the meaning specified in the Sale Process.

"Successful Bidder" has the meaning specified in the Sale Process.

"Tax Act" means the *Income Tax Act* (Canada), as amended and any relevant legislation of a province imposing tax similar to the *Income Tax Act* (Canada).

"Tax Returns" means any and all returns, reports, declarations, elections, notices, forms, designations, filings, and other documents filed or required to be filed in respect of Taxes.

"Taxes" means (i) any and all taxes, duties, fees, excises, premiums, assessments, imposts, levies, rates, withholdings, dues, contributions and other charges, collections or assessments of any kind whatsoever; (ii) all interest, penalties, fines, additions to tax or other additional amounts imposed on or in respect of amounts of the type described in clause (i) or (ii) above; and (iii) any liability for the payment of any amounts of the type described in clauses (i) or (ii) above as a result of any express or implied obligation to indemnify any other Person or as a result of being a transferee or successor in interest to any party.

"Transferred Employees" means Offerees who accept offers of employment given in accordance with this Agreement from the Purchaser.

"Vendor" has the meaning specified in the recitals above.

"Wages" has the meaning specified in Section 6.4(d).

Section 1.2 References and Usage.

Unless expressly stated otherwise, in this Agreement:

- (a) reference to a gender includes all genders;
- (b) the singular includes the plural and vice versa;
- (c) "or" is used in the inclusive sense of "and/or";
- (d) "any" means "any and all";
- (e) the words "including", "includes" and "include" mean "including (or includes or include) without limitation";
- (f) the phrase "the aggregate of", "the total of", "the sum of", or a phrase of similar meaning means "the aggregate (or total or sum), without duplication, of";
- (g) \$ or dollars refers to the Canadian currency unless otherwise specifically indicated;
- (h) a statute includes all rules and regulations made under it, if and as amended, re-enacted or replaced from time to time;
- (i) a Person includes its predecessors, successors and permitted assigns;
- (j) the term "notice" refers to written notices except as otherwise specified;
- (k) the term "Agreement" and any reference in this Agreement to this Agreement or any other agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may from time to time be amended, restated, replaced, supplemented or novated and all schedules to it, except as otherwise provided in this Agreement; and
- (l) whenever payments are to be made or an action is to be taken on a day which is not a Business Day, such payment will be required to be made or such action will be required to be taken on or not later than the next succeeding Business Day and in the computation of periods of time, unless otherwise stated, the word "from" means "from and excluding" and the words "to" and "until" each mean "to and including".

Section 1.3 Headings, etc.

The use of headings (e.g. Article, Section, etc.) in this Agreement is reference only and is not to affect the interpretation of this Agreement. References in the Agreement to Article, Section etc., unless otherwise specified, shall mean the applicable Article, Section, etc. of this Agreement.

Section 1.4 Schedules.

The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it:

Schedule 1.1(a)	Assumed Contracts
Schedule 1.1(b)	Consent Required Contracts
Schedule 1.1(c)	Excluded Assets
Schedule 1.1 (d)	Excluded Contracts
Schedule 1.1 (e)	Assumed Liabilities
Schedule 1.1 (f)	Intellectual Property
Schedule 1.1 (g)	Licenses
Schedule 1.1 (h)	Sale Process
Schedule 2.1(a.1)	Personal and moveable property
Schedule 2.1(a.2)	Required Accessories
Schedule 2.2(h)	Claims

ARTICLE 2 PURCHASE AND SALE

Section 2.1 Purchased Assets.

Subject to the terms and conditions of this Agreement, the Vendor agrees to sell, assign and transfer to the Purchaser and the Purchaser agrees to purchase from the Vendor on the Closing Date, on an "as is, where is" basis, all of the Vendor's right, title and interest in the Vendor's property, assets and undertakings of every kind and description and wheresoever situate, of the Business, other than the Excluded Assets (collectively, the "**Purchased Assets**"), free and clear of all Encumbrances. Without limiting the forgoing, the Purchased Assets shall include:

- (a) **Equipment and Supplies.** All computer hardware, supplies, accessories, and other tangible personal and moveable property including suppliers' lists, computers and equipment provided to and used by the Employees, all inventory in the storage unit or elsewhere, the 280 VitalVials owned by the Vendor and used in connection with the Business, as well as all further VitalVials provided to customers, former customers, and research partners of the Business, all of which are listed in Schedule 2.1(a.1), the magnet switches, VitalVial cases, USB cables, USB hubs, and Notebooks which consist of the accessories required for the VitalQC system and any materials or components which may have been bought in advance for the purpose of building new vials, all of which are listed in Schedule 2.1 (a.2);
- (b) **Contracts and Customer Lists.** All Assumed Contracts and all rights, title, interests and obligations thereunder;
- (c) **Computer Software.** All software and documentation used in the Business, including, all electronic data processing systems, program specifications, input data, report layouts, formats, the VitalMetric and VitalApp algorithms and source code together with all administrator rights, the algorithm for the VitalVial Tracker and source code together with all administrator rights, the clinical research and all other data gathered in connection with the Business, including record file layouts, diagrams, functional specifications, narrative descriptions, flow charts, operating manuals and all other rights, licenses and information necessary to transfer the know-how in connection with the

Business, including access to the cloud applications with all of the providers to the Business, including but not limited to AWS, Go Daddy, GitLab and SSL, as well as all usernames and access codes, workarounds and methods to fix the code used in connection with the Business as well as the data collected through the VitalMetric and VitalApp;

- (d) **Cash and Accounts Receivable.** All cash in the bank accounts of the Vendor and all accounts receivable (including unbilled revenue from work in progress), bills receivable, contractual hold-backs, trade accounts, trade debts and book debts due or accruing due in connection with the Business, including any refunds and rebates receivable relating to the Business or the Purchased Assets and the full benefit of all security (including cash deposits), guarantees and other collateral held by the Vendor relating to the Business, and amounts receivable (or which may become receivable) by the Vendor under royalty agreements or other agreements or documents related thereto and all bank accounts;
- (e) **Prepaid Expenses.** All prepaid expenses of the Business;
- (f) **Intellectual Property.** All right, title and interest of the Vendor in and to the Intellectual Property owned by or licensed to the Vendor for use in connection with the Business or the Purchased Assets, including domain names and telephone numbers and as otherwise described in the foregoing;
- (g) **Books and Records.** The Books and Records of the Vendor related to the Business and the Purchased Assets;
- (h) **Claims.** All claims of the Vendor relating to the Business or the Purchased Assets whether choate or inchoate, known or unknown, contingent or otherwise, as listed in Schedule 2.1(h);
- (i) **Tax Refunds.** The proceeds of any and all refundable Taxes payable or paid by the Vendor net of any amounts withheld by any taxing authority, and any claim or right of the Vendor to any refund, rebate, or credit of Taxes;
- (j) **Goodwill.** The goodwill of the Business, including the exclusive right of the Purchaser to represent itself as carrying on the Business in continuation of and in succession to the Vendor (including all business names related thereto);
- (k) **CASL.** All consents, whether express or implied, granted in favour of the Vendor in accordance with *An Act to promote the efficiency and adaptability of the Canadian economy by regulating certain activities that discourage reliance on electronic means of carrying out commercial activities, and to amend the Canadian Radio-television and Telecommunications Commission Act, the Competition Act, the Personal Information Protection and Electronic Documents Act and the Telecommunications Act* (Canada) (commonly known as "Canada's Anti-Spam Law" or "CASL");
- (l) **Insurance.** The interest of the Vendor in: (i) all contracts of insurance, insurance policies and insurance plans which are assets of or maintained in connection with the Purchased Assets; (ii) any insurance proceeds net of any deductibles recovered by the Vendor under all other contracts of insurance, insurance policies (excluding D&O policies) and insurance plans between the date of this Agreement and the Closing Date; and (iii) the full benefit of the

Vendor's rights to insurance claims relating to the Business and amounts recoverable in respect thereof net of any deductible to the extent any of the foregoing are transferable;

- (m) **Warranty Rights.** All warranty rights against manufacturers or suppliers relating to any of the Purchased Assets; and
- (n) **Other Property.** All other property, assets and undertakings of the Vendor of whatever nature or kind used in connection with the Business and/or the Purchased Assets, other than the Excluded Assets.

Section 2.2 Excluded Assets.

The Purchased Assets shall not include any of the following assets (collectively, the "Excluded Assets"):

- (a) the Excluded Contracts listed in Schedule 1.1 (d); and
- (b) the Excluded Assets listed on Schedule 1.1 (c).

Section 2.3 Assignment and Assumption of Consent Required Contracts.

- (a) Notwithstanding anything in this Agreement, the Purchaser shall not assume and has no obligation to discharge any liability or obligation under or in respect of any Consent Required Contract unless: (a) the consent, approval or waiver of the party or parties to such Consent Required Contract (other than the Vendor) required to assign such Consent Required Contract has been obtained on terms satisfactory to the Purchaser, acting reasonably and the value of such Consent Required Contract has enured to the Purchaser; or (b) such Consent Required Contract is subject to an Assignment Order.
- (b) The Vendor and the Purchaser shall use reasonable commercial efforts to obtain the consent, approval or waiver of the party or parties to each Consent Required Contract (other than the Vendor) to the assignment of such Consent Required Contract prior to the filing of the motion materials for the Approval and Vesting Order. For greater certainty, neither the Vendor nor the Purchaser is under any obligation to pay any money, incur any obligations, commence any legal proceedings (other than as set forth below with respect to Assignment Orders), or offer or grant any accommodation (financial or otherwise) to any third party in order to obtain any such consent, approval or waiver.
- (c) In the event that the consent, approval or waiver required to assign any Consent Required Contract is not obtained before the date the motion materials are filed for the Approval and Vesting Order, the Vendor shall, at the request of the Purchaser and prior to Closing, seek the Assignment Order for such Consent Required Contract in form and substance satisfactory to the Vendor and the Purchaser, each acting reasonably.
- (d) Subject to Closing, in the event that the consent to assign any Consent Required Contract is not obtained and the Vendor is required to obtain the Assignment Order for one or all of the Consent Required Contracts, the Purchaser shall pay the applicable Cure Costs related to such Consent Required Contracts on Closing.

ARTICLE 3 PURCHASE PRICE

Section 3.1 Purchase Price.

The purchase price payable by the Purchaser to the Vendor for the Purchased Assets (the "Purchase Price") shall be the total of:

- (a) a payment in cash of \$40,000.00 which shall be provided to Royal Bank of Canada, the secured creditor, to satisfy the debt related to the secured interest; and
- (b) a credit for the balance owing on the DIP Agreement (currently \$360,000.00 plus interest), together with any additional debtor in possession financing as provided by the DIP Lender and approved by the Court;

Section 3.2 Payment of the Purchase Price.

The Purchaser shall pay and satisfy the Purchase Price:

- (a) at Closing, by the payment in cash; and
- (b) at Closing, by the payment of the amount of the DIP Loan owing by the Vendor to the DIP Lender.

Section 3.3 Purchase Price Allocation.

The Purchase Price shall be allocated among the Purchased Assets in the manner and form advised by the Purchaser on the Closing Date. Such allocation shall be binding and the Purchaser and Vendor shall report the purchase and sale of the Purchased Assets and file all filings which are necessary or desirable under the Tax Act to give effect to such allocations and shall not take any position or action inconsistent with such allocation.

Section 3.4 No Effect on Other Rights.

The determination of the Purchase Price in accordance with the provisions of this Article will not limit or affect any other rights or causes of action either the Purchaser or the Vendor may have with respect to the representations, warranties or covenants in its favour contained in this Agreement.

ARTICLE 4 TAX MATTERS

Section 4.1 Transfer Taxes.

The Purchaser shall be liable for and shall pay all sales Taxes and all other similar Taxes properly payable upon and in connection with the sale, assignment and transfer of the Purchased Assets from the Vendor to the Purchaser, other than any taxes payable on the Vendor's net income, profits or gains for all fiscal years for which the Vendor is required to make tax filings prior to Closing.

Section 4.2 Tax Elections.

The Parties shall use their commercially reasonable efforts in good faith to minimize (or eliminate) any taxes payable under the *Excise Tax Act* (Canada) in respect of the Closing by, among other things, making such elections and taking such steps as may be provided for under that Act, including, for greater certainty, making a joint election in a timely manner under Section 167 of that Act, under Section 22 of the Tax Act and under Subsections 20(24) and 20(25) of the Tax Act (and the corresponding sections of any provincial legislation) as may reasonably be requested by the Purchaser in connection with the Closing.

ARTICLE 5 REPRESENTATIONS AND WARRANTIES

Section 5.1 Representations and Warranties of the Vendor.

The Vendor represents and warrants as follows to the Purchaser and acknowledges and agrees that the Purchaser is relying upon the representations and warranties in connection with its purchase of the Purchased Assets.

- (a) **Incorporation and Qualification.** The Vendor is a corporation incorporated and existing under the laws of jurisdiction of its formation. The Vendor has the corporate power and authority to own and operate its property, carry on its business and, subject to Court approval, enter into and perform its obligations under this Agreement and each of the Ancillary Agreements to which it is a party.
- (b) **Corporate Authorization.** Subject to the issuance of the Approval and Vesting Order, the execution and delivery of and performance by the Vendor of this Agreement and each of the Ancillary Agreements to which it is a party and the consummation of the transactions contemplated by them have been duly authorized by all necessary and corporate action on the part of each of them.
- (c) **Execution and Binding Obligation.** Subject to the issuance of the Approval and Vesting Order, this Agreement and each of the Ancillary Agreements to which the Vendor is a party have been duly executed and delivered by the Vendor and constitute legal, valid and binding agreements of it, enforceable against it in accordance with their respective terms.
- (d) **Residence of the Vendor.** The Vendor is not a non-resident of Canada within the meaning of the *Tax Act*. The Vendor is not a non-Canadian within the meaning of the *Investment Canada Act*.
- (e) **HST Registrant.** The Vendor is a registrant for the purposes of the tax imposed under Part IX of the *Excise Tax Act* (Canada) and its registration number is 815034574.
- (f) **Taxes.** The Vendor has, in accordance with applicable Laws, invoiced, collected, withheld, reported and remitted to the appropriate tax authority all

Taxes which are due and payable by the Vendor. There are no liens for Taxes against the Purchased Assets. None of the Purchased Assets is the subject of any trust arising under any Law relating to Taxes.

- (g) **Disclosure of all Purchased Assets.** The Vendor has fully disclosed to the Purchaser all Purchased Assets. The Schedules to this Agreement are complete in all respects.

Section 5.2 Representations and Warranties of the Purchaser.

The Purchaser represents and warrants as follows to the Vendor and acknowledges and agrees that the Vendor is relying on such representations and warranties in connection with its sale of the Purchased Assets:

- (a) **Incorporation and Corporate Power.** The Purchaser is an entity that is duly formed and validly existing under the laws of the jurisdiction of its formation, has full power and capacity to own the Purchased Assets and to carry on the Business as now conducted has the power and authority to enter into and perform its obligations under this Agreement and each of the Ancillary Agreements to which it is a party.
- (b) **Corporate Authorization.** The execution and delivery of and performance by the Purchaser of this Agreement and each of the Ancillary Agreements to which it is a party and the consummation of the transactions contemplated by them have been duly authorized by all necessary action on the part of the Purchaser.
- (c) **Execution and Binding Obligation.** This Agreement and each of the Ancillary Agreements to which the Purchaser is a party have been duly executed and delivered by the Purchaser and constitute legal, valid and binding agreements of the Purchaser, enforceable against it in accordance with their respective terms subject only to any limitation under applicable Laws relating to (i) bankruptcy, winding-up insolvency, arrangement, fraudulent preference and conveyance, assignment and preference and other similar laws of general application affecting creditors' rights, and (ii) the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.
- (d) **HST Registrant.** The Purchaser will be as at Closing, a registrant for the purposes of the tax imposed under Part IX of the *Excise Tax Act* (Canada).

Section 5.3 No Other Representations or Warranties.

The representations and warranties given by the Vendor in Section 5.1 are the only representations and warranties of the Vendor in connection with this Agreement and the transactions contemplated by it. Except for the representations and warranties given by the Vendor in Section 5.1, the Purchaser is purchasing the Purchased Assets on an "as is, where is" basis and does not rely upon any statements, representations, promises, warranties, conditions or guarantees whatsoever by the Vendor or the Proposal Trustee, whether express or implied (by operation of law or otherwise), oral or written, legal, equitable, conventional, collateral or otherwise, regarding any of the assets to be acquired or any of the liabilities to be assumed or the completeness of any information provided in connection therewith.. No

representation, warranty or condition is expressed or can be implied as to title, encumbrances, description, fitness for purpose, merchantability, condition, quantity or quality or in respect of any other matter or thing whatsoever concerning the Purchased Assets and the Business.

Section 5.4 AS IS, WHERE IS.

THE PURCHASER ACKNOWLEDGES AND AGREES THAT, EXCEPT AS EXPRESSLY SET FORTH HEREIN, THE PURCHASED ASSETS AND THE BUSINESS ARE PURCHASED ARE ASSUMED BY THE PURCHASER "AS IS, WHERE IS" AS THEY SHALL EXIST AT THE CLOSING DATE WITH ALL FAULTS AND WITHOUT ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, IN FACT OR BY LAW WITH RESPECT TO THE PURCHASED ASSETS AND THE BUSINESS, AND WITHOUT ANY RECOURSE TO ANY OF THE VENDOR, THE PROPOSAL TRUSTEE OR ANY OF THEIR DIRECTORS, OFFICERS, SHAREHOLDERS, EMPLOYEES, AGENTS, REPRESENTATIVES OR ADVISORS, OTHER THAN FOR FRAUD, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT. THE PURCHASER AGREES TO ACCEPT THE PURCHASED ASSETS AND THE BUSINESS IN THE CONDITION, STATE AND LOCATION THEY ARE IN ON THE CLOSING DATE BASED ON THE PURCHASER'S OWN INSPECTION, EXAMINATION AND DETERMINATION WITH RESPECT TO ALL MATTERS AND WITHOUT RELIANCE UPON ANY EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE MADE BY OR ON BEHALF OF OR IMPUTED TO ANY OF THE VENDOR OR THE PROPOSAL TRUSTEE, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT. Unless specifically stated in this Agreement, the Purchaser acknowledges and agrees that no representation, warranty, term or condition, understanding or collateral agreement, whether statutory, express or implied, oral or written, legal, equitable, conventional, collateral or otherwise, is being given by the Vendor or Proposal Trustee in this Agreement or in any instrument furnished in connection with this Agreement, as to description, fitness for purpose, sufficiency to carry on any business, operate, merchantability, quantity, condition, ownership, quality, value, suitability, durability, environmental condition, assignability or marketability thereof, or in respect of any other matter or thing whatsoever, and all of the same are hereby expressly excluded.

**ARTICLE 6
PRE-CLOSING COVENANTS OF THE PARTIES**

Section 6.1 Access by Purchaser.

Subject to applicable Law, from the date that this Agreement is selected, or deemed to be selected as, the Successful Bid in accordance with the Sale Process until the Closing, the Vendor shall upon reasonable notice, permit the Purchaser and its partners, its and their respective employees, agents, counsel, accountants or other representatives, lenders, potential lenders and potential investors to have reasonable access during normal business hours to (i) the premises of the Vendor; (ii) the Purchased Assets, including all Books and Records and all minute books and corporate records of the Vendor using commercially reasonable efforts; (iii) the Assumed Contracts; and (iv) furnish to the Purchaser or its partners, employees, agents, counsel, accountants or other representatives, lenders, potential lenders and

potential investors such financial and operating data and other information with respect to the Purchased Assets and the Vendor (to the extent such data or information is in the Vendor's possession or, using commercially reasonable efforts, can be obtained by the Vendor or the Proposal Trustee) as the Purchaser from time to time reasonably requests.

Section 6.2 Access by Proposal Trustee.

From the Closing Date, the Purchaser shall, upon reasonable notice, permit representatives of the Proposal Trustee to have reasonable access during normal business hours to the Books and Records for the purpose of completing its mandate as the Proposal Trustee from time-to-time reasonably requests.

Section 6.3 Title and Risk.

The Purchased Assets shall remain at the risk of the Vendor until Closing and at the risk of the Purchaser from and after Closing. The Vendor covenants to the Purchaser that, during the period from and including the date hereof through and including the Closing Date or the earlier termination of this Agreement, the Vendor shall use commercially reasonable efforts to conduct the Business in substantially the same manner as conducted as of the date hereof.

Section 6.4 Employees.

- (a) The Purchaser shall, prior to the Closing Date, offer employment conditional on Closing and effective as of the Closing Date to all of the Employees whom the Purchaser wishes, in its sole discretion (subject to the requirements of applicable Law, if any), to employ after the Closing (collectively, the "Offerees") on such employment terms and conditions as the Purchaser considers appropriate or as may be required in accordance with applicable Law.
- (b) At least two (2) Business Days prior to the Closing Date, the Purchaser shall provide the Vendor and the Proposal Trustee with a schedule setting forth a list of the names of all Offerees.
- (c) The Vendor shall terminate the employment of all Employees no later than the Closing.
- (d) Prior to the Closing Date, the Vendor shall process, or cause to be processed, the payroll for, and pay (or cause to be paid), all compensation, including the base wages, base salary, bonuses, vacation pay and ordinary course sales commissions for all Employees (collectively, "Wages") as and when due for the period prior to Closing. The Vendor shall withhold and remit all applicable payroll taxes and deductions from Wages at source as required by Law.
- (e) Following the Closing, the Purchaser shall process the payroll for, and pay (or cause to be paid), as and when due, (i) all unpaid Wages accrued but which did not become due prior to the Closing Date with respect to each Transferred

Employee; and (ii) all Wages accrued on and after the Closing Date with respect to each Transferred Employee.

- (f) All Non-Transferred Employee Liabilities shall be dealt with in the Proposal Proceedings or any subsequent bankruptcy of the Vendor in accordance with the entitlement and priority afforded to such claims under applicable Law. The Purchaser shall not assume or be liable for any Non-Transferred Employee Liabilities.

Section 6.5 Notices and Requests for Consents.

- (a) Subject to the selection or deeming of this Agreement as the Successful Bid in accordance with the Sale Process, the Vendor shall use its commercially reasonable efforts to obtain or cause to be obtained prior to Closing, at its expense, all consents, approvals and waivers that are required by the terms of the Consent Required Contracts, or an Assignment Order in order to complete the transactions contemplated by this Agreement.
- (b) The Vendor and the Proposal Trustee shall provide notices (in form and substance acceptable to the Purchaser, acting reasonably) that are required by the terms of the Assumed Contracts in connection with the transaction contemplated pursuant to the Approval and Vesting Order and this Agreement.

Section 6.6 Transfer of the Purchased Assets.

The Vendor shall take all necessary steps and proceedings to permit title to the Purchased Assets to be duly and validly transferred and assigned to the Purchaser at the Closing pursuant to the Approval and Vesting Order and this Agreement, free from all Encumbrances.

Section 6.7 Actions to Satisfy Closing Conditions.

- (a) The Vendor shall use its commercially reasonable efforts to take or cause to be taken all such actions so as to ensure compliance with all of the conditions set forth in Section 8.1.
- (b) The Purchaser shall use its commercially reasonable efforts to take or cause to be taken all such actions so as to ensure compliance with all of the conditions set forth in Section 8.2.

**ARTICLE 7
SALES PROCESS**

Section 7.1 Compliance with Sale Process.

The Parties each agree to comply with the Sale Process.

Section 7.2 Expense Reimbursement.

- (a) In consideration for the Purchaser's expenditure in the preparation of this Agreement, and in performing due diligence with respect to the Vendor and the

Purchased Assets, if this Agreement is terminated pursuant to Section 10.1(1) or Section 10.1(2)(b), then the Vendor shall reimburse the Purchaser for its expenses reasonably incurred in connection with this Agreement up to a maximum amount of \$35,000.00 (the "Expense Reimbursement").

- (b) The Purchaser agrees that the Expense Reimbursement will be the sole and exclusive remedy of the Purchaser against the Vendor in the event that this Agreement is terminated pursuant to Section 10.1(1) or Section 10.1(2)(b).
- (c) If the Purchaser is not selected as, or deemed to be, the Successful Bidder, the Vendor shall request that the order of the Court approving the sale of the assets of the Vendor to the Successful Bidder to include a provision requiring that the Expense Reimbursement be paid to the Purchaser in accordance with the Sale Process and that the payment of the Expense Reimbursement be approved as part of such sale and not be voidable as a matter of bankruptcy law or otherwise.
- (d) The Vendor shall seek the approval of the Court to the transactions contemplated by this Agreement in accordance with the following:
 - (i) Promptly upon execution of this Agreement, the Vendor shall seek approval of the (i) Sale Process; (ii) filing of this Agreement as a "Stalking Horse Bid"; and (iii) the Expense Reimbursement.
 - (ii) The Vendor and the Purchaser acknowledge that: (i) this Agreement and the transactions contemplated herein are subject to Court approval; and (ii) Closing the transactions contemplated herein is subject to this Agreement being determined to be the Successful Bid in accordance with the Sale Process and to the issuance of the Approval and Vesting Order.
 - (iii) As soon as practicable if the Purchaser is selected as, or deemed to be, the Successful Bidder, the Vendor shall file motion materials seeking the issuance of the Approval and Vesting Order.
 - (iv) If the Purchaser is selected, or deemed to be selected as the Successful Bidder, as soon as practicable, the Purchaser shall advise the Vendor and the Proposal Trustee in writing of the Consent Required Contracts for which the Purchaser requires the Vendor to seek an Assignment Order.
 - (v) The Vendor and the Purchaser shall cooperate with filing and serving the motion for issuance and entry of the Approval and Vesting Order and any Assignment Orders required pursuant to Section 2.3(c).
 - (vi) The Vendor, in consultation with the Purchaser, shall determine all Persons required to receive notice of the motions for the Approval and Vesting Order and Assignment Order, as applicable under applicable Laws and the requirements of the BIA, the Court and any other Person determined necessary by the Vendor or the Purchaser.

ARTICLE 8
CONDITIONS OF CLOSING

Section 8.1 Conditions for the Benefit of the Purchaser.

The purchase and sale of the Purchased Assets is subject to the following conditions being satisfied on or prior to the Closing Date, which conditions are for the exclusive benefit of the Purchaser and may be waived, in whole or in part, by the Purchaser in its sole discretion:

- (a) **Successful Bid.** The Purchaser shall have been selected as, or deemed to be, the Successful Bidder, following the completion of the Sale Process.
- (b) **Truth of Representations and Warranties.** The representations and warranties of the Vendor contained in this Agreement were true and correct, in all material respects, as of the date of this Agreement and as of the Closing Date with the same force and effect as if such representations and warranties had been made on and as of such date and the Vendor shall have executed and delivered a certificate of a senior officer to that effect. Upon the delivery of such certificate, the representations and warranties of the Vendor in Section 5.1 will be deemed to have been made on and as of the Closing Date with the same force and effect as if made on and as of such date.
- (c) **Performance of Covenants.** The Vendor shall have fulfilled or complied, in all material respects, with all covenants contained in this Agreement required to be fulfilled or complied with by it at or prior to the Closing, and the Vendor shall have executed and delivered a certificate of an authorized representative to that effect.
- (d) **Consents for Consent Required Contracts.** All consents, approvals or waivers for each Consent Required Contract shall have been obtained on terms acceptable to the Purchaser, acting reasonably, or an Assignment Order will have been obtained in respect thereof. All such consents, approvals, waivers or Assignment Orders will be in force and will not have been modified, rescinded, appealed or stayed.
- (e) **No Bankruptcy.** The Vendor shall not be and shall not have become a bankrupt under the BIA.
- (f) **Legal Action.** There shall be no order issued by any Governmental Authority delaying, restricting or preventing consummation of the transactions contemplated herein.
- (g) **Deliveries.** The Vendor shall have delivered or caused to be delivered to the Purchaser the following in form and substance satisfactory to the Purchaser acting reasonably:
 - (i) consents to the assignment of the Consent Required Contracts to the extent that an Assignment Order was not obtained;
 - (ii) the certificates referred to in Section 8.1(b) and Section 8.1(c);
 - (iii) the issued and entered Approval and Vesting Order, which order shall not have been modified, rescinded, appealed or stayed;

- (iv) a copy of the Proposal Trustee's Certificate (such certificate shall be filed with the Court by the Proposal Trustee following Closing and a copy of such filed Proposal Trustee's Certificate shall be delivered to the Purchaser promptly thereafter);
- (v) the originals of the Books and Records, excluding those Excluded Assets but including all Tax Returns pertaining to corporate income Taxes of the Vendor for the previous 5 years from the Closing Date, that are available to the Vendor using commercially reasonable efforts;
- (vi) the Purchased Assets, which shall be delivered *in situ*, other than the cash held in the Vendor's bank accounts on the Closing Date, which shall be transferred to the Purchaser; and
- (vii) an assignment and assumption agreement, bill of sale or such other conveyances, assignments, documents and instruments of transfer as may be reasonably required by the Purchaser to complete the transaction contemplated herein.

Section 8.2 Conditions for the Benefit of the Vendor.

The purchase and sale of the Purchased Assets is subject to the following conditions being satisfied on or prior to the Closing Date, which conditions are for the exclusive benefit of the Vendor and may be waived, in whole or in part, by the Vendor in its sole discretion.

- (a) **Truth of Representations and Warranties.** The representations and warranties of the Purchaser contained in this Agreement were true and correct, in all material respects, as of the date of this Agreement as of the Closing Date with the same force and effect as if such representations and warranties had been made on and as of such date and the Purchaser shall have executed and delivered a certificate of a senior officer to that effect. Upon delivery of such certificate, the representations and warranties of the Purchaser in Section 5.2 will be deemed to have been made on and as of the Closing Date with the same force and effect as if made on and as of such date.
- (b) **Performance of Covenants.** The Purchaser shall have fulfilled or complied, in all material respects, with all covenants contained in this Agreement required to be fulfilled or complied with by it at or prior to Closing and the Purchaser shall have executed and delivered a certificate of a senior officer to that effect.
- (c) **Deliveries.** The Purchaser shall have delivered or caused to be delivered to the Vendor the following in form and substance satisfactory to the Vendor, acting reasonably:
 - (i) all resolutions of the board of directors of the Purchaser approving the entering into and completion of the transactions contemplated by this Agreement and the Ancillary Agreements;
 - (ii) a certificate of status, compliance, good standing or like certificate with respect to the Purchaser issued by appropriate government official of the jurisdiction of its incorporation; and
 - (iii) the certificates referred to in Section 8.2(a) and Section 8.2(b).

- (d) **Proceedings.** All proceedings to be taken in connection with the transactions contemplated in this Agreement and any Ancillary Agreement are reasonably satisfactory in form and substance to the Vendor, acting reasonably, and the Vendor shall have received copies of all the instruments and other evidence as it may reasonably request in order to establish the consummation of such transactions and the taking of all proceedings in connection therewith.
- (e) **Legal Action.** There shall be no order issued by any Governmental Authority delaying, restricting or preventing consummation of the transactions contemplated herein.

Section 8.3 Conditions for the Benefit of the Purchaser and the Vendor.

The purchase and sale of the Purchased Assets is subject to the following conditions being satisfied on or prior to the Closing Date, which conditions are for the benefit of both the Vendor and the Purchaser and may be jointly waived, in whole or in part, by the Vendor and the Purchaser.

- (a) **Approval and Vesting Order.** The Approval and Vesting Order shall have been obtained and shall not have been appealed, set aside, varied or stayed or, if appealed or stayed, all appeals shall have been dismissed and all stays shall have been lifted, respectively.
- (b) **Proposal Trustee's Certificate.** The Proposal Trustee shall have delivered the Proposal Trustee's Certificate confirming the satisfaction of all conditions under this Agreement, payment of the Purchase Price and the vesting of the Purchased Assets pursuant to the Approval and Vesting Order.

ARTICLE 9 CLOSING

Section 9.1 Date, Time and Place of Closing.

Closing will take place on the Closing Date by exchanging signature pages of the Parties electronically or at the offices of counsel to the Vendor in Toronto, Ontario, or at such other place, on such other date and at such other time as may be consented to by the Proposal Trustee and agreed upon in writing between the Vendor and the Purchaser, including remotely.

Section 9.2 Closing Procedures.

Subject to satisfaction or waiver by the relevant Party of the conditions of closing, on the Closing Date, the Closing shall be deemed completed upon the delivery of the Proposal Trustee's Certificate.

Section 9.3 Proposal Trustee's Certificate.

The Parties hereby acknowledge and agree that the Proposal Trustee shall be entitled to file a certificate, substantially in the form attached to the Approval and Vesting Order (the "**Proposal Trustee's Certificate**"), with the Court upon receiving written confirmation from the Purchaser and the Vendor that all conditions of Closing have been satisfied or waived.

ARTICLE 10 TERMINATION

Section 10.1 Termination Rights.

- (1) This Agreement will be terminated automatically, without any action by either Party, if:
 - (a) this Agreement is not selected as the Successful Bid pursuant to and in accordance with the terms of the Sale Process; or
 - (b) if the Approval and Vesting Order, is not granted by December 20, 2024, or such later date as may be agreed to be the Parties.
- (2) This Agreement may, by Notice in writing given on or prior to the Closing Date, be terminated:
 - (a) by mutual consent of the Vendor and the Purchaser;
 - (b) by the Purchaser, if:
 - (i) there has been a material breach of this Agreement by the Vendor and where such breach is capable of being cured, such breach has not been waived by the Purchaser in writing or cured within 15 days following written Notice of such breach by the Purchaser; or
 - (ii) any of the conditions in Section 8.1 have not been satisfied and it becomes reasonably apparent that any of such conditions will never be satisfied (other than as result of the failure of the Purchaser to perform any of its material obligations) and the Purchaser has not waived such condition in writing at or prior to Closing;
 - (c) by the Vendor, if:
 - (i) there has been a material breach of this Agreement by Purchaser and where such breach is capable of being cured, such breach has not been waived by the Vendor in writing or cured within 15 days following written Notice of such breach by the Vendor; or
 - (ii) any of the conditions in Section 8.2 have not been satisfied and it becomes reasonably apparent that any of such conditions will never be satisfied (other than as result of the failure of the Vendor to perform any of its material obligations) and the Vendor has not waived such condition in writing at or prior to Closing.

Section 10.2 Effect of Termination.

The rights of termination under this Article 10 are, subject to Section 7.2(b), in addition to any other rights the respective Party may have under this Agreement or otherwise, and the exercise of a right of termination by a Party will not constitute an election of remedies. If this Agreement is terminated pursuant to Section 10.1, this Agreement will be of no further force or effect; provided, however, that Section 7.2(b) (*Expense Reimbursement*), this Section 10.2 (*Effect of Termination*), and Article 11 (*Miscellaneous*) and provisions that by their nature should survive, will survive the termination of this Agreement.

- 25 -
ARTICLE 11
MISCELLANEOUS

Section 11.1 Notices.

Any notice, direction or other communication given regarding the matters contemplated by this Agreement (each a "Notice") must be in writing, sent by personal delivery, courier or email addressed:

- (a) to the Purchaser at:
AEROCOM GMBH & CO.
Adam-Riesse-Strasse 26
D-73529
Schabisch Gmund, Germany
Attn: Roland Pfitzer
roland.pfitzer@aerocom.de

With a copy by email to:

JacobLaw
Hohenzollernstrasse 84, 80801 Munich
Att'n: Sylvia A. Jacob
Email: sj@jacoblaw.com

- (b) to the Vendor at:
MOTRYX INC.
1505 Barrington St. Suite 101
Halifax, NS
B3J 3K5

Attn: Niva Sabeshan
Email: n.sabeshan@motryx.com

with copies by email to:

BOYNECLARKE LLP
99 Wyse Road - Suite 600
Dartmouth, NS
B4A 2S5

Attn: Joshua J. Santimaw
Email: jsantimaw@boyneclarke.ca

- (c) to the Proposal Trustee at:
BDO CANADA LIMITED
Clayton Professional Centre
255 Lacewood Dr.
Halifax, NS
B3M 4G2

Attn: Neil Jones, CPA, CA, CIRP, LIT

Email: nejones@bdo.ca

with a copy by email to:

Stephen.kingston@mcinnescooper.com

A Notice is deemed to be given and received (i) if sent by personal delivery or courier, on the date of delivery if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in the place of receipt) and otherwise on the next Business Day; or (ii) if sent email, on the next Business Day. A Party may change its address for service from time to time by providing a Notice in accordance with the foregoing. Any subsequent Notice must be sent to the Party at its changed address. Any element of a Party's address that is not specifically changed in a Notice will be assumed not to be changed. Sending a copy of a Notice to a Party's legal counsel as contemplated above is for information purposes only and does not constitute delivery of the Notice to that Party.

Section 11.2 Time of the Essence.

Time shall be of the essence in respect of the obligations of the Parties arising prior to Closing under this Agreement.

Section 11.3 Third Party Beneficiaries.

Except as otherwise provided in this Agreement, (i) the Vendor and the Purchaser intend that this Agreement will not benefit or create any right or cause of action in favour of any Person, other than the Parties; and (ii) no Person, other than the Parties, is entitled to rely on the provisions of this Agreement in any action, suit, proceeding, hearing or other forum. The Parties reserve their right to vary or rescind the rights at any time and in any way whatsoever, if any, granted by or under this Agreement to any Person who is not a Party, without notice to or consent of that Person.

Section 11.4 Expenses.

Except as otherwise expressly provided in this Agreement, each Party will pay for its own costs and expenses (including the fees and expenses of legal counsel, accountants and other advisors) incurred in connection with this Agreement or any Ancillary Agreements and the transactions contemplated by them.

Section 11.5 Amendments.

This Agreement may only be amended, supplemented or otherwise modified by written agreement signed by the Vendor and the Purchaser.

Section 11.6 Waiver.

No waiver of any of the provisions of this Agreement or any Ancillary Agreement will constitute a waiver of any other provision (whether or not similar). No waiver will be binding unless executed in writing by the Party to be bound by the waiver. A Party's acceptance of any certificate delivered on Closing or failure or delay in exercising any right under this Agreement will not operate as a waiver of that. A single or partial exercise of any right will not preclude a Party from any other or further exercise of that right or the exercise of any other right.

Section 11.7 Entire Agreement.

This Agreement and the other documents executed in connection herewith constitutes the entire agreement between the Parties with respect to the transactions contemplated in this Agreement and supersede all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties with respect to such transactions. There are no representations, warranties, covenants, conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Parties in connection with the subject matter of this Agreement, except as specifically set forth in this Agreement. The Parties have not relied and are not relying on any other information, discussion or understanding in entering into and completing the transactions contemplated by this Agreement.

Section 11.8 Successors and Assigns.

- (1) Upon execution of the Agreement by the Parties, it will be binding upon and enure to the benefit of the Vendor, the Purchaser and their respective successors and permitted assigns.
- (2) Except as provided in this Section 11.8, neither this Agreement nor any of the rights or obligations under this Agreement may be assigned or transferred, in whole or in part, by any Party without the prior written consent of the other Party. Upon giving Notice to the Vendor at any time on or prior to the Closing Date, the Purchaser may assign this Agreement or any of its rights and/or obligations under this Agreement to any of its Affiliates, provided that such Affiliate and the Purchaser shall be jointly and severally liable with respect to all of the obligations of the Purchaser, including the representations, warranties, covenants, indemnities and agreements of the Purchaser.

Section 11.9 Severability.

If any provision of this Agreement is determined to be illegal, invalid or unenforceable by an arbitrator or any court of competent jurisdiction, from which no appeal exists or is taken, that provision will be severed from this Agreement and the remaining provisions will remain in full force and effect.

Section 11.10 Governing Law and Jurisdiction.

- (1) This Agreement is governed by and will be interpreted and construed in accordance with the laws of the Province of Nova Scotia and the federal laws of Canada applicable therein.
- (2) Each Party irrevocably attorns and submits to the exclusive jurisdiction of the Court (and appellate courts therefrom) and waives objection to the venue of any proceeding in such court or that such court provides an inappropriate forum.

Section 11.11 Counterparts.

This Agreement may be executed in any number of counterparts, each of which is deemed to be an original, and such counterparts together constitute one and the same instrument. Transmission of an executed signature page by facsimile, email or other electronic means is as effective as a manually executed counterpart of this Agreement.

[Remainder of page intentionally left blank. Signature pages follow.]

IN WITNESS WHEREOF the Parties have executed this Asset Purchase Agreement.

MOTRYX INC.

By: 

Authorized Signing Officer

AEROCOM GMBH & CO.

By: 

Authorized Signing Officer

Aerocom GmbH & Co.
Communicationssysteme
Ham-Kluse-Straße 10
35229 Schwelm (Germany)
Telefon (0 71 71) 10 45-0
Telefax (0 71 71) 10 45-299

SCHEDULES

Schedule 1.1(a) – Assumed Contracts

1. The following subscription agreements:

- a. Monthly subscription with Plooto for the accounts payable software;
- b. Monthly subscription with Microsoft for the Microsoft Office Suite;
- c. Subscription with Xero for the accounts receivable and invoicing software;
- d. Monthly and annual subscriptions with Slack for team and internal communication system;
- e. Subscription with Dext for the accounting software;
- f. Monthly subscription with Wagepoint for payroll software;
- g. Subscription with FedEx for shipping services;
- h. Yearly subscription with Adobe Acrobat for the document management system;
- i. Monthly subscription with Pipedrive for the customer relationship management system
- j. Monthly subscription with AWS for hosting the software infrastructure;
- k. Annual subscriptions with GoDaddy for the application domain, motryx.app, motryx.com, motryx.info and Motryx.io;
- l. Annual subscription with SSL.com for frontend and backend communication encryption services;
- m. Subscription with Gitlab for the IT version control of the source code;

2. The following customer agreements and relationships:

- a. Order Form addressed to Aarhus Universitetshospital, effective October 9, 2023, in connection with order number 0026, to the extent any work in connection with this order is still outstanding, and generally any ongoing subscription with Aarhus Universitetshospital;
- b. Work related to the invoices number INV-0046 from April 3, 2024, addressed to Aerocom UK, and INV-0051 from June 10, 2024, addressed to Aerocom UK Ltd, to the extent any work in connection with those invoices is still outstanding, and generally any ongoing subscription from Aerocom UK or Aerocom UK Ltd;
- c. Reseller Agreement with Aerocom GmbH & Co effective November 2, 2020, and generally any ongoing subscription from Aerocom GmbH & Co.;
- d. Purchase orders SYX5206998 from April 15, 2024, and SYC5388888 from August 21, 2024, both issued by Alberta Health Services, to the extent any work in connection with those orders is still outstanding, and generally any ongoing subscription from Alberta Health Services or Alberta Precision Labs - Arthur Child Cancer Centre;
- e. Order Form addressed to Dept. Clinical Biomchemistry, effective November 5, 2019, in connection with order number 4529191, the work related in the invoice number INV-0022 from May 31, 2023, addressed to Bispebjerg Hospital, as well as the Amendment #1 addressed to Bispebjerg Hospital, effective January 6, 2024, in connection with order

number 0050, to the extent any work in connection with these documents is still outstanding, and generally any ongoing subscription from Dept. Clinical Biochemistry or Bispebjerg Hospital;

- f. Order Form addressed to Region Skåne Medicinsk Service, effective November 5, 2020, in connection with order number 4619111, as well as the work related in the invoice number INV-0038 from December 1, 2023, addressed to Lund Region Skåne, to the extent any work in connection with these documents is still outstanding, and generally any ongoing subscription from Region Skåne Medicinsk Service or Lund Region Skåne;
 - g. Purchase order P000980195 from October 24, 2024, issued by Roche Diagnostics International Ltd, as well as the work related to invoice number INV-0045 from February 2, 2024, addressed to Roche Diagnostics International AG, to the extent any work in connection with those documents is still outstanding, and generally any ongoing subscription from Roche Diagnostics International Ltd or Roche Diagnostics International AG;
 - h. Generally any ongoing subscription from Telecom;
 - i. Purchase orders 47448640 from June 28, 2021 and 100511719 from April 20, 2024, issued by PennMedicine – University of Pennsylvania Health System, as well as invoice number INV-0048 from April 9, 2024, addressed to University of Penn Health System – UPenn Health, to the extent any work in connection with those documents is still outstanding, and generally any ongoing subscription from PennMedicine – University of Pennsylvania Health System;
3. The Use Agreement with Metro Self-Storage - Joseph Zatzman Dr dated November 8, 2024, pertaining to Account No.L0062145, for a storage unit located at 201 Joseph Zatzman Dr Dartmouth, NS B3B 1R5, Canada
4. The following confidentiality and non-disclosure agreements:
- a. Aerocom UK Ltd., including the agreement effective February 22, 2024;
 - b. F. Jon Geske, PhD, including the agreement effective August 19, 2019;
 - c. Alexander Lujt Man. BV, including the agreement executed on February 17, 2020;
 - d. Odense University Hospital;
 - e. Benjamin Otto, including the agreement effective August 19, 2019;
 - f. Liz Maria Arcila Osejo, including the agreement effective January 1, 2019;
 - g. Alan Archibald, including the agreement effective January 1, 2019;
 - h. Shad Bay Solutions Inc, including the agreement effective January 21, 2020;
 - i. Aerocom GmbH & Co., including the agreement executed on June 8 and August 9, 2020;
 - j. David MacKinnon, including the agreement effective December 14, 2018;
 - k. Michael Dowd, including the agreement effective January 1, 2019;
 - l. Andrew Lynch, including the agreement effective August 29, 2019;

- m. Corum Group Intl. S.á.r.l, including the agreement executed on August 22, 2019
- n. Dale Robertson, including the agreement effective January 1, 2019;
- o. Washington University, including the agreement effective April 9, 2019;
- p. SmartSkin;
- q. Greiner Bio-One GmbH, including the agreement executed on October 16, 2019;
- r. Abbott Laboratories, including the agreement executed on September 5 and 9, 2019;
- s. DynaLife, including the agreement executed on November 28, 2019;
- t. SmartSkin Technologies, including the agreement effective April 23, 2019;
- u. Sygehus Lillebælt, Afdeling for Biokemi og Immounologi, including the agreement executed August 20, 2020;
- v. Lamson Concepts, including the agreement effective August 4, 2020;
- w. Razzberry Inc., including the agreement effective April 22, 2021;
- x. Bio-Rad Laboratories, Inc., including the agreement effective September 5, 2019;
- y. Laboratory Corporation of America Holdings, including the agreement executed May 15 and 17, 2019;
- z. Atelier Palais Inc.;
- aa. Piet Meijer, including the agreement effective March 23, 2021;
- bb. Reeldata Inc., including the agreement effective April 2, 2019;
- cc. Becton, Dickinson and Company, including the agreement effective March 13, 2019.

Schedule 1.1(b) – Consent Required Contracts

NIL.

Schedule 1.1(c) – Excluded Assets

NIL.

Schedule 1.1(d) – Excluded Contracts

Any contractual relationship between Motryx Inc. and Labquality Oy, including but not limited to:

1. Order Form effective May 1, 2021, in connection with order number 3512121, executed on April 12, 2021, by Mr. Juha-Pekka Nuutinen, CEO of Labquality Oy at the time, and Ms. Franziska Broell, CEO of Motryx Inc. at the time;
2. Any contractual relationship referenced in the invoices number INV-0041 from January 9, 2024 and December 12, 2023, issued by Motryx Inc. to Labquality Oy;
3. Generally any other form of subscription already purchased by Labquality Oy from Motryx Inc.

Schedule 1.1(e) – Assumed Liabilities

NIL.

Schedule 1.1(f) – Intellectual Property

All intellectual property of the Vendor used by or currently being developed for use in the Business relating to the VitalQC technology, and all rights, interests and benefits of the Vendor, through ownership, licensing or otherwise to such Intellectual Property, including without limitation:

1. all patents, patent applications and other patent rights, including provisional and continuation patents, including but not limited to:

Country/Region	CatchWord	Inventors	Current Owners	Application No.	Priority No.	Priority Date
International	SENSOR DEVICE FOR DETECTING TRANSPORT PARAMETERS AND METHOD OF MAKING THE SAME	Andre Bezanson Franziska Broell	Unknown	WO 2020/181375 A9	62/818050 3036791 3037423 62/811,169 62/949,695	
Canada	DEVICE WITH ENCAPSULATED SENSOR AND METHOD OF MAKING THE SAME	Andre Bezanson Franziska Broell	Motryx Inc.	3036791		
Canada	DEVICE WITH ENCAPSULATED SENSOR AND METHOD OF MAKING THE SAME	Andre Bezanson Franziska Broell	Andre Bezanson Franziska Broell	3037423	62/818050	Mar. 13, 2019
Europe	DEVICE WITH ENCAPSULATED SENSOR AND METHOD OF MAKING THE SAME	Andre Bezanson Franziska Broell Sunga Park Christopher Dall	Motryx Inc.	20770352.1	62/818050	Mar. 13, 2019
United States	SENSOR DEVICE FOR DETECTING TRANSPORT PARAMETERS AND METHOD OF MAKING THE SAME	Andre Bezanson Franziska Broell Sunga Park Christopher Dall	Motryx Inc.	17/438312	62/818050	Mar. 13, 2019
Canada	SYSTEM, COMPUTER-READABLE MEDIUM, AND METHOD FOR VALIDATING A BLOOD VIAL TRANSIT ROUTE	Andre Bezanson Franziska Broell Benjamin Scheifele	Andre Bezanson Franziska Broell Benjamin Scheifele	3173862	63/242415	

2. all registered and unregistered trademarks, service marks, logos, slogans, corporate names, business names and other indicia of origin, and all applications and registrations therefor, including but not limited to:

Country/Region	Trademark	Class	Registration No.	Registration Date	Affidavit of Continued Use	Renewal Deadline
United States	MOTRYX	009	6207153	November 24, 2020	November 24, 2026	November 24, 2030, and each 10 year anniversary thereafter
United States	MOTRYX	042	6349168	May 11, 2021	May 11, 2027	May 11, 2031, and each 10 year anniversary thereafter

United States	VITALVIAL	009	6307154	November 24, 2020	November 24, 2026	November 24, 2030, and each 10 year anniversary thereafter
United States	VITALVIAL	042	6356896	May 18, 2021	May 18, 2027	May 18, 2031, and each 10 year anniversary thereafter
United Kingdom	MOTRYX	009, 042	UK00918143528	October 28, 2019	February 27, 2020	October 28, 2029, and each 10 year anniversary thereafter
United Kingdom	VITALVIAL	009, 042	UK00918143541	October 28, 2019	February 27, 2020	October 28, 2029, and each 10 year anniversary thereafter
EUTM	MOTRYX	009, 042	018143528	October 28, 2019	February 27, 2020	October 28, 2029, and each 10 year anniversary thereafter
EUTM	VITALVIAL	009, 042	018143541	October 28, 2019	February 27, 2020	October 28, 2029, and each 10 year anniversary thereafter

3. registered and unregistered copyrights and mask works, including all copyright in and to computer software programs and applications and registrations of such copyright;
4. internet domain names, applications and reservations for internet domain names, uniform resource locators and the corresponding internet sites, including but not limited to motryx.app, motryx.com, motryx.info and Motryx.io;
5. industrial designs;
6. trade secrets and proprietary information not otherwise listed in (a) through (e) above, including, without limitation, all inventions (whether or not patentable), invention disclosures, moral and economic rights of authors and inventors (however denominated), confidential information, technical data, in-house assembly manuals and work descriptions, customer lists, sales strategies, pricing schemes, corporate and business names, trade names, trade dress, brand names, know-how, mask works, circuit topography, formulae, methods (whether or not patentable), designs, processes, procedures, technology, business methods, source codes, object codes, computer software programs (in either source code or object code form), databases, data collections and other proprietary information or material of any type, and all derivatives, improvements and refinements thereof, howsoever recorded or unrecorded, including but not limited to the following documents:
 - a. The following lists and summaries:
 - i. VitalQC Inventory 11_2024.xlsx
 - ii. VitalQC Inventory 12_2024.xlsx
 - iii. Motryx Client List_Active and Non Active_112724.xlsx
 - iv. MOTRYX Open Contracts Nov 2024.pdf

v. Motryx Supplier_Client 112024_DR.xlsx

b. The following case studies and posters:

- i. ARUP moves towards replacing blood for PTS monitoring with VitalQC.pdf
- ii. Bispebjerg Hospital_Streamlining Clinical Validation with VitalQC.pdf
- iii. Copenhagen Study.pdf
- iv. Differences in pneumatic tube system impact on blood samples emphasizes need for quality contro.pdf
- v. Motryx - Sheffield's Northern General Hospital Cast Studt v20.pdf
- vi. Odense University Hospital.pdf
- vii. Poster_EuroMedLab 2023_PTS_1080x1920_Final[11].pdf
- viii. Telecom Case Study.pdf
- ix. Vital QC helps determine Best Carrier Inserts For Three European Laboratories.pdf;

c. The following presentation materials, reports and publications:

- i. Vitalqc_Intro_DR.pdf
- ii. VitalQC_How it Works_DR.pdf
- iii. VitalQC_Cost Opportunity_Customer Support.pdf
- iv. ISO_WG_Liaison_Report_29_Oct_20.pdf
- v. ISO_WG_Guidance_Update_Slides_15_Sep_20.pdf
- vi. ISO_WG_LTD_Project_Presentation_28_Oct_20.pdf
- vii. ISO_WG_Convenors_Report_28_Oct_20.pdf
- viii. Gils et al. 2019 Use of clinical data and acceleration profiles to validate pneumatic transportation systems.pdf

d. The following sales and strategy materials:

- i. Sales Strategy 2024-2025_DR .pdf
- ii. Motryx Regulatory Strategy.pptx

e. The following brand and logo materials:

- i. 190923 Motryx user experience Courier.pdf

- ii. 190923 Motryx user experience PTS.pdf
- iii. 170628 Social Headers_LinkedIn 1.png
- iv. 170628 Social Headers_LinkedIn 2.png
- v. 190718 Motryx Illustrations-04.png
- vi. Levey-Jennings.jpg
- vii. Motryx Illustration Diagram updated-06.png
- viii. Pitch Slides.pdf
- ix. twitter background 1.jpg
- x. 190925 Motryx VitalFlyer.pdf
- xi. 190609 Motryx Brand guidelines.pdf

f. The following promotional items:

- i. Vitalqc_Intro_DR.pdf
- ii. VitalQC_vs_Competitor.pdf
- iii. 190827 Motryx Whitepaper (1).pdf
- iv. 200617 Case Study_Motryx (1).pdf

g. The following white papers:

- i. Gils et al. 2019 Use of clinical data and acceleration profiles to validate pneumatic transportation systems.pdf
- ii. 190827 Motryx Whitepaper (1).pdf

h. The following methods, procedures, guidelines and designs:

- i. Cient Onboarding Template_ VitalApp.pdf
- ii. Shipping Procedure.pdf
- iii. Approved_AABB Guide to Pneumatic Tube Delivery Systems_Validation and Use to Transport Blood Components.pdf
- iv. PRE06_Validation_of_External_Transport_Systems_Project_proposal.docx
- v. PRE06_Call_for_Volunteers.docx
- vi. ISO15189_Draft_CD2_October26.pdf

- vii. Collated_comments_ISIRI.doc
- viii. Collated_Comments_Batch_2_May_2020.docx
- ix. Collated_Comments_Batch_1_April_2020.docx
- x. N829_ISO_15189_CD2.docx
- xi. SABS_comments_with_responses.doc
- xii. ISO_commenting_Outcome.docx
- xiii. ISO_commenting_template - FB.docx
- xiv. ISO-TC212_WG1_N0597_Comments.pdf
- xv. ISO_commenting_template - ERIN and FRAN COMMENTS.doc
- xvi. ISO_commenting_Outcome.docx
- xvii. ISO_commenting_template - Lee.doc
- xviii. ISO_commenting_template - FB.docx
- xix. ISO_CD_15189.docx
- xx. Guiding_principles_for_the_revision_of_ISO_15189.docx
- xxi. Code Reviews.docx
- xxii. Hardware Assembly Process.docx
- xxiii. Information Security Standards - v2.docx
- xxiv. P62679US00 - DRAFT Drawings (PDF).pdf
- xxv. P62679US00 - DRAFT Specification.docx
- xxvi. Shipment Process.docx
- xxvii. Support Process.docx
- xxviii. VitalVial Assembly.pages
- xxix. vitalvial repair.pages
- xxx. 20191216_hardware_engineering_requirement.docx
- xxxi. 20191218_hardware_system_design_document.docx
- xxxii. Motryx VitalVial - New Process Review - 20.May.2020.pdf
- xxxiii. 20200214_power_budget.docx

- xxxiv. 20200214_sensors.docx
- xxxv. 20200226_system_architecture_design.docx
- xxxvi. Design files
- xxxvii. Project Logs for VT1_4
- xxxviii. Project Outputs for VT1_4
- xxxix. VT1_4_Sheets
 - xl. VT1_4.OutJob
 - xli. VT1_4.PrjPcb
 - xlii. VT1_4.PrjPcbStructure
 - xliii. EEMB files
 - xliv. 20200416_PO_sunsel.pdf
 - xlvi. ICOD Payment and Processing_ UPS - United States.pdf
 - xlvi. INV 15897 MOTRYX .pdf
 - xlvi. Motryx AUTH# 086646 (Paid by Visa).pdf
 - xlvi. Q-5956 - Motryx - Encapsulation assembly using vials x 12 - 02-07-20.pdf
 - xlix. r7pr3cg_p2vUn.pdf
 - i. PKCELL files
 - ii. 20200522_VT1.3_Data_Validation_Protocol.docx
 - lii. 20200522_VT1.3_Impact_Validation_Protocol.docx
 - liii. Controlled Firmware.pptx
 - liv. Data Transfer Mechanism.docx
 - lv. Data Transfer Mechanism.pdf
 - lvi. Dataformat.docx
 - lvii. Dataformat.pdf
 - lviii. Document.docx
 - lix. Firmware Design.docx

- lx. Firmware Updates.docx
- lxi. Interaction between VitalVial and VitalApp through commands and response.docx
- lxii. Sensor Control.docx
- lxiii. Task Management.docx
- lxiv. Hardware Team Expense Proposal.pdf
- lxv. Hardware Transactions and Vendors.xlsx
- lxvi. Patent Application Supporting Documents
- lxvii. Safety Data Sheets

- 7. any applications or registrations of the foregoing, issued patents, continuations in part, divisional applications or analogous rights therefor, in each case whether registered or not; and
- 8. all Licenses in respect to any intellectual property;
- 9. any software or other proprietary information or document embedded in a laptop currently held by the Vendor or by one of its former or current employees.

Schedule 1.1(g) – Licenses

The following subscription agreements:

1. Monthly subscription with Plonto for the accounts payable software;
2. Monthly subscription with Microsoft for the Microsoft Office Suite;
3. Subscription with Xero for the accounts receivable and invoicing software;
4. Monthly and annual subscriptions with Slack for team and internal communication system;
5. Subscription with Dext for the accounting software;
6. Monthly subscription with Wagepoint for payroll software;
7. Yearly subscription with Adobe Acrobat for the document management system;
8. Monthly subscription with Pipedrive for the customer relationship management system
9. Monthly subscription with AWS for hosting the software infrastructure;
10. Annual subscriptions with GoDaddy for the application domain, motryx.app, motryx.com, motryx.info and Motryx.io;
11. Annual subscription with SSL.com for frontend and backend communication encryption services;
12. Subscription with Gitlab for the IT version control of the source code;

Schedule 1.1(h) – Sale Process

Schedule 2.1(a.1) – Personal and moveable property

All computer hardware, supplies, accessories, and other tangible personal and moveable property including suppliers' lists, computers and equipment provided to and used by the Employees, all inventory in the storage unit or elsewhere, the 280 VitalVials owned by the Vendor and used in connection with the Business, as well as all further VitalVials provided to customers, former customers, and research partners of the Business, including but not limited to:

1. The laptop, monitor, keyboard and mice provided to Ms. Nivashini Sabeshan and Ms. Wendy Casson;
2. The inventory in the storage unit located at 201 Joseph Zatzman Dr Dartmouth, NS B3B 1R5, Canada
3. The following vials in circulation:

Label	Manufacture	Version	Model	Firmware	Institute	# of Vials
VT123134	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Aarhus Universitetshospital	1
VT123135	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Aarhus Universitetshospital	1
VT123136	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Aarhus Universitetshospital	1
VT123138	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Aarhus Universitetshospital	1
VT1278	28.01.2020	VT1.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12109	28.04.2020	VT1.2.1	PTS	v1.2-237.1f996cd	Aerocom	1
VT12111	28.04.2020	VT1.2.1	PTS	v1.2-237.1f996cd	Aerocom	1
VT12211	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12212	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12213	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12231	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12215	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12218	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12230	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12221	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12223	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12225	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12226	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom	1
VT12309	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Aerocom	1
VT12319	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Aerocom	1
VT12339	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Aerocom	1
VT12349	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Aerocom	1
VT12113	28.04.2020	VT1.2.1	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT12320	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT12224	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT1244	28.01.2020	VT1.2	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT1267	10.03.2020	VT1.2	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT12100	28.04.2020	VT1.2.1	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT12104	28.04.2020	VT1.2.1	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT12209	23.07.2020	VT1.2.2	PTS	v1.2-237.1f996cd	Aerocom UK	1
VT123113	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Alberta Precision Labs (Arthur Child Cancer Centre)	1
VT123118	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Alberta Precision Labs (Arthur Child Cancer Centre)	1
VT123127	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Alberta Precision Labs (Arthur Child Cancer Centre)	1
VT12397	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Alberta Precision Labs (Arthur Child Cancer Centre)	1
VT123124	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Alberta Precision Labs (Arthur Child Cancer Centre)	1
VT12350	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12354	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12356	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12357	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12365	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12375	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12381	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12395	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Bispebjerg Hospital	1
VT12367	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Cambridge	1
VT12146	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Cambridge	1
VT12353	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Cambridge	1
VT12358	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996cd	Cambridge	1
VT123101	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Curacao	1
VT123102	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996cd	Curacao	1
VT12308	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Curacao/Aerocom	1
VT12327	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996cd	Curacao/Aerocom	1

VT1201	31.10.2019	VT1.2	PTS	v1.2-237.1096ed	R&D/Courier/Product Development - Not for sale	1
VT1205	03.09.2019	VT1.2	PTS	v1.2-237.1096ed	R&D/Courier/Product Development - Not for sale	1
VT1208	21.08.2019	VT1.2	PTS	v1.2-237.1096ed	R&D/Courier/Product Development - Not for sale	1
VT1213	03.09.2019	VT1.2	PTS	v1.2-237.1096ed	R&D/Courier/Product Development - Not for sale	1
VT0012	05.07.2019	VT1.0	PTS	v1.0-177.d1ee298	Felix Lazaren	1
VT1220	28.01.2020	VT1.2	PTS	v1.2-237.1096ed	Genetec Hospital	1
VT1243	28.01.2020	VT1.2	PTS	v1.2-237.1096ed	Genetec Hospital	1
VT1274	10.03.2020	VT1.2	PTS	v1.2-237.1096ed	R&D/Courier/Product Development - Not for sale	1
VT1218	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1221	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1234	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1227	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1228	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1233	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1234	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1239	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1247	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT1248	09.09.2019	VT1.2	COURIER	v1.2-237.1096ed	LabCorp - courier model	1
VT12300	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12303	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12304	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12306	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12311	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12312	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12313	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12314	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12316	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12321	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12324	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12325	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12333	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12334	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12335	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12336	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12341	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12342	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12343	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12377	14.10.2021	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12380	14.10.2021	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT123137	17.08.2022	VT1.2.3	PTS	v1.2-237.1096ed	labquality	1
VT12338	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	Lund	1
VT12396	14.10.2021	VT1.2.3	PTS	v1.2-237.1096ed	Lund	1
VT123139	17.08.2022	VT1.2.3	PTS	v1.2-237.1096ed	Lund	1
VT123147	17.08.2022	VT1.2.3	PTS	v1.2-237.1096ed	Lund	1
VT12346	27.11.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12348	27.11.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12344	27.11.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12345	27.11.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1255	10.03.2020	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12340	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12372	14.10.2021	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT123123	17.08.2022	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1012	06.08.2019	VT1.0	PTS	v1.0-177.d1ee325	Motryx available inventory	1
VT1237	09.11.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1200	21.08.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1202	21.08.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1203	24.09.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1210	24.09.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1223	05.09.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1226	11.10.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT1232	11.10.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT1236	11.10.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT1241	09.09.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1242	11.10.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT1252	30.01.2020	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1260	19.09.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1271	10.03.2020	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1284	07.10.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1291	25.11.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT1292	07.10.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1296	07.10.2019	VT1.2	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT1298	11.10.2019	VT1.2	COURIER	v1.2-237.1096ed	Motryx available inventory	1
VT12315	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12317	07.12.2020	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT12379	14.10.2021	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1
VT123110	17.08.2022	VT1.2.3	PTS	v1.2-237.1096ed	Motryx available inventory	1

[illegible]

VT1249	28.01.2020	VT1.2	PTS	v1.2-237.1f996ed	Roche	1
VT1254	10.03.2020	VT1.2	PTS	v1.2-237.1f996ed	Roche	1
VT1263	10.03.2020	VT1.2	PTS	v1.2-237.1f996ed	Roche	1
VT12210	23.07.2020	VT1.2.3	PTS	v1.2-237.1f996ed	Roche	1
VT12383	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Sheffield Hospital	1
VT123109	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sheffield Hospital	1
VT123119	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sheffield Hospital	1
VT123129	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sheffield Hospital	1
VT12399	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Sunnybrook	1
VT123122	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sunnybrook	1
VT123125	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sunnybrook	1
VT123131	17.08.2022	VT1.2.3	PTS	v1.2-237.1f996ed	Sunnybrook	1
VT1268	10.03.2020	VT1.2	PTS	v1.2-237.1f996ed	Uniklinikum Salzburg	1
VT1273	10.03.2020	VT1.2	PTS	v1.2-237.1f996ed	Uniklinikum Salzburg	1
VT1245	28.01.2020	VT1.2	PTS	v1.2-237.1f996ed	Universität Greifswald	1
VT1254	28.01.2020	VT1.2	PTS	v1.2-237.1f996ed	Universität Greifswald	1
VT1279	07.10.2019	VT1.2	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT1280	07.10.2019	VT1.2	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT12381	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT12385	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT12386	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT12390	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Uniklinikum Leipzig	1
VT1219	07.10.2019	VT1.2	PTS	v1.2-237.1f996ed	R&D/Courier/Product Development - Not for sale	1
VT1225	04.11.2019	VT1.2	PTS	v1.2-237.1f996ed	R&D/Courier/Product Development - Not for sale	1
VT12326	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12328	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12339	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12330	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12331	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12332	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	UPenn	1
VT12323	07.12.2020	VT1.2.3	PTS	v1.2-237.1f996ed	Wendy	1
VT12398	14.10.2021	VT1.2.3	PTS	v1.2-237.1f996ed	Wendy	1
Totals						235

Schedule 2.1(a.2) – Accessories

The magnet switches, Vital Vial cases, USB cables, USB hubs, and Notebooks which consist of the accessories required for the VitalQC system, and any materials or components which may have been bought in advance for the purpose of building new vials, including but not limited to:

[illegible]

[illegible]

[illegible]

Schedule 2.1(h) – Claims

All claims of the Vendor relating to the Business or the Purchased Assets whether choate or inchoate, known or unknown, contingent or otherwise, including but not limited to claims for outstanding payments from Roche Diagnostics International Ltd, Roche Diagnostics International AG and Labquality Oy in connection with subscriptions from those companies existing at the Closing Date.

Schedule "B"

Form of Non-Disclosure Agreement

RECIPROCAL CONFIDENTIALITY & NON-DISCLOSURE AGREEMENT

THIS AGREEMENT DATED as of the ____ day of _____, 202__

BETWEEN:

MOTRYX INC

-and-

XXXXXX

WHEREAS Motryx Inc. and XXXXX have entered into or are considering entering into a business transaction;

AND WHEREAS it may be necessary for one party (the "Disclosing Party") to disclose to the other party (the "Recipient") from time-to-time certain Confidential Information (as hereinafter defined);

AND WHEREAS Motryx Inc. and XXXXX, respectively, desire to maintain the confidentiality of any Confidential Information disclosed to it by the other party, and to induce each party to disclose its Confidential Information, each party is willing to agree to accept the disclosure of Confidential Information on a confidential basis under the terms and conditions of this Agreement;

THEREFORE in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, Motryx Inc. and XXXX agree as follows:

1. Definition of Confidential Information

- 1.01 Subject to Section 1.02 below, "Confidential Information" shall mean any information disclosed or provided by either party to the other party, consisting of information relating to the business, financial condition, operations or affairs of Motryx Inc., any other of its affiliates, subsidiaries and related entities, or the business, financial condition, operations or affairs of XXXX. By way of example but not by way of limitation, Confidential Information includes corporate records, financial data, technical data, research and development projects and results, marketing approaches, marketing plans and materials, products, processes, operations, any proprietary documentation, formulas, codes, flow charts, software, computer instructions, techniques, models, information, diagrams, know-how, trade secrets, data, designs, formats, analyses, strategies, forecasts and names, addresses, employee information and any customer information. Confidential Information includes not only written information, but information transferred orally, visually, electronically or by any other means. All information will be Confidential Information if it is so marked or otherwise identified as such, or when by its very nature, it deals with matters that if generally known to competitors, would be damaging to the party who provided the information.

1.02 Confidential Information shall not include the following:

- (a) Information which was already in the Recipient's possession before disclosure by the Disclosing Party, and said information was received by the Recipient without the obligation of confidence;
- (b) Information which is developed independently by the Recipient without use of or reference to the Disclosing Party's Confidential Information;
- (c) Information which is or becomes publicly available without breach of this Agreement by the Recipient; and
- (d) Information which is rightfully received by the Recipient from a third party that had no obligation of confidence with respect to such information.

2. Use of Confidential Information

2.01 Neither party shall, either directly or indirectly, use the Confidential Information for the design or creation of any product or service, or use the Confidential Information in any other manner or for any purpose other than to evaluate a proposed business relationship between the parties or as reasonably required for the purposes of an existing business relationship between the parties.

2.02 Neither party shall, during the term of this Agreement, or at any time following termination of this Agreement for any reason whatsoever, use any Confidential Information to solicit any business from the customers of the other party or any of its affiliates, subsidiaries and related entities.

3. Disclosure of Confidential Information

3.01 The Recipient shall keep the Confidential Information of the Disclosing Party in strict confidence. The Recipient party shall not directly or indirectly disclose, allow access to, transmit, or transfer the Confidential Information of the Disclosing Party to a third party except; (i) to those of its employees, directors or agents who have an actual need to know the Confidential Information for the purposes of the business relationship, or (ii) where prior written consent is provided by the Disclosing Party. The Recipient shall ensure that anyone who it discloses the Disclosing Party's Confidential Information to has agreed to receive and use the Confidential Information on substantially similar conditions as contained in this Agreement.

3.02 In the event that the Recipient is legally compelled to disclose any of the Disclosing Party's Confidential Information, it shall cooperate with the Disclosing Party by providing it with prompt written notice of such requirement so that the Disclosing Party may seek a protective order or other appropriate remedy. In the event that such protective order or other remedy is not obtained, the Recipient agrees to furnish only that portion of the Confidential Information, which is legally required, and such disclosure will not result in any liability hereunder.

4. Rights in Confidential Information

- 4.01 All rights, title and interest in and to the Confidential Information shall remain the exclusive property of the Disclosing Party, and nothing contained in this Agreement shall be construed as granting any rights, by license or otherwise, to any Confidential Information disclosed pursuant to this Agreement.

5. Breach of Agreement, Liabilities and Remedies

- 5.01 Each party shall promptly report to the other party any actual or suspected breach of this Agreement and will take all reasonable measures requested by the other party to prevent, control or remedy any such breach.
- 5.02 The Recipient will be liable for all costs, expenses and damages arising from any intentional disclosure of the Disclosing Party's Confidential Information and any unintentional disclosure of such Confidential Information where the Recipient did not exercise a reasonable and prudent standard of care.
- 5.03 Each party agrees that money damages may not be a sufficient remedy for any breach of this Agreement by either party and that the other party may be entitled, in addition to any other rights or remedies that it may have, to equitable relief, including injunction and specific performance, in the event of any breach of this Agreement. Such remedy shall not be deemed to be the exclusive remedy for a breach of this Agreement but shall be in addition to all other remedies available at law or in equity.

6. Return of Confidential Information

- 6.01 Upon the earlier to occur of: (i) the expiration or termination of this Agreement, or (ii) written request by the Disclosing Party, the Recipient will make no further use of the Disclosing Party's Confidential Information and shall immediately return or destroy all such Confidential Information in its possession, custody or control, including any and all copies or duplicates of the Confidential Information.

7. Term of Agreement

- 7.01 This Agreement and each party's obligations under this Agreement shall survive until three (3) years from the date of this Agreement, or one (1) year from the date of termination of the business transaction or relationship, whichever is later.

8. Governing Law

- 8.01 This Agreement shall be governed by, subject to, interpreted and enforced in all respects in accordance with the laws which apply in the province of Nova Scotia, and the parties shall submit to the jurisdiction of the courts of the province of Nova Scotia for any litigation arising under this Agreement.

9. Miscellaneous

- 9.01 This Agreement shall not constitute any guarantee, representation or warranty, express or implied to either party with respect to the value, completeness or accuracy of the Confidential Information.
- 9.02 The entering into of this Agreement shall not constitute any obligation on the part of either party to enter into any further agreement with the other party.
- 9.03 This Agreement shall not be construed as a teaming, joint venture, agency, partnership or such arrangement. Nothing in this Agreement shall grant to either party the right to make commitments of any kind for or on behalf of the other party without the prior written consent of that other party.
- 9.04 If it is held by a court or other lawful authority of competent jurisdiction that any provision of this Agreement or part thereof is void, illegal, invalid or unenforceable then such provision or part shall be deemed stricken, and the remaining provisions shall be severable and remain valid, in full force and effect.
- 9.05 Neither party to this Agreement shall assign this Agreement or any rights or obligations under this Agreement without the prior written consent of the other party, and any attempt to do so without consent shall be null, void and of no effect.
- 9.06 This Agreement shall be binding upon and enure to the benefit of the respective successors and permitted assigns of each party.
- 9.07 No provision of this Agreement shall be deemed waived, and no breach excused, unless such waiver or consent excusing the breach shall be in writing and signed by the party to be charged with such waiver or consent. The failure of either party to demand strict performance by the other party of any of the provisions of the Agreement will not be a waiver or relinquishment of any rights under this Agreement. Either party may at any later time demand strict and complete performance by the other party of the Agreement.
- 9.08 This Agreement shall be constructed in accordance with the plain meaning of its language and neither for nor against the drafting party.
- 9.09 For any notice under this Agreement to be effective it must be made in writing and sent to the address of the appropriate party set out above, unless such party has notified the other party, in accordance with the provisions of this section, of a new mailing address.
- 9.10 This Agreement may not be amended or modified except in writing signed by both parties hereto.
- 9.11 This Agreement may be executed in several electronic counterparts, each of which when so executed shall constitute an original and all of which together shall constitute one and the same agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first set forth above.

MOTRYX INC.

By: _____

Name: Niva Sabeshan

Title: President

XXXXXXX

**IN THE SUPREME COURT
COUNTY OF HALIFAX, N.S.**

I hereby certify that the foregoing is a true copy of the original order on file herein.

Dated the 20 day of December
A.D., 2024


DEPUTY REGISTRAR

SHYLA FURLONG
Deputy Registrar of
Bankruptcy